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The solution structure of domain IIa of the hepatitis C virus internal ribosome 
entry site in complex with a racemic benzimidazole inhibitor was determined by NMR 
spectroscopy with corroborating fluorescence data.  A 38 base RNA construct 
representing the inhibitor-binding region of domain IIa was synthesized by T7 RNA 




N labeled and isotopically unlabeled RNA 
samples were produced and studied in complex with the inhibitor. 
 The inhibitor was previously shown to have inhibitory activity in an HCV 
replicon assay.  It was also previously found to bind in the bulge region of domain IIa.  In 
the free RNA, this five base bulge region introduces a bend in the extended domain II 
that situates the terminus of the domain over the mRNA cleft in the ribosomal E site.  
This hinge-like bulge region is not a known binding site for any host or viral translational 
cofactors, but domain II has been shown to be critical for IRES function, and the bulge-
induced bend in domain IIa has been shown to be important for IRES function in 
mutagenesis assays. 
 Molecular dynamics refinement in explicit solvent and subsequent free energetic 
analysis indicate that the inhibitor enantiomers bind with comparable affinity and 
equivalent binding modes.  The structure of this inhibitor/RNA complex suggests that the 
small molecule rearranges the base stacking in the bulge and introduces a significant 
conformational change that eliminates the bent RNA helical trajectory.  This suggests a 
 iv 
 
possible mechanism of inhibition involving the displacement of the domain II terminus 
from the mRNA cleft on the ribosomal E site.  Perhaps most importantly, this structure 
may serve as a guide in the development of second-generation higher affinity inhibitors 
of the hepatitis C IRES as well as provide general insights into small molecule inhibitor 
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The World Health Organization estimates that 3% of the world’s population is 
afflicted by the hepatitis C virus (HCV).  Roughly 55-85% of infected patients develop 
chronic infections.  Of those, 5-20% will develop cirrhosis and 1-2% will develop liver 
cancer. The virus is primarily spread through exposure to infected blood, but has been 




Current treatment of hepatitis C consists of injection of interferon or pegylated 
interferon along with oral administration of ribavirin.  There are serious side effects.  This 
course of treatment can take several months and has mixed results depending on such 
factors as viral genotype and patient ethnicity.  Average success rates are slightly greater 
than 50% as measured by sustained virological response (absence of detectable HCV 
RNA in serum by the end of treatment cycle).
1
 The inefficacy of current therapies in 
treating some patients coupled with the general lack of broadly effective drugs for HCV 
highlight the need for new and better therapeutic alternatives.
2, 3







Hepatitis C is a positive-stranded RNA virus and a member of the hepacivirus 
genus of the Flaviviridiae family.  The mode of viral entry into the cell is still not fully 
understood, but it is widely accepted that the host cell receptor proteins CD81 and SR-BI, 
and the tight junction protein claudin-1 are involved.4-6 Having gained entry into the 
hepatocyte, the positive sense RNA genome can be released and translated into an 
approximately 3000 amino acid polyprotein which is subsequently cleaved and processed 
by host signal peptidases into four known structural (Core, E1, E2, p7) and six known 
non-structural (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) proteins.7 HCV employs an 
internal ribosome entry site (IRES) in the 5’ untranslated region (UTR) of its genome to 
initiate ribosomal translation in a manner distinct from that of endogenous mRNA.  HCV 
utilizes the viral RNA dependent RNA polymerase NS5B in conjunction with host factors 
to produce negative sense copies of its genome.  These RNAs then serve as templates to 
produce a greater number of positive sense genomic copies.7
Viral assembly is still poorly understood, but is known to ultimately result in an 
immature virion consisting of encapsidated positive sense RNA in the cytoplasm.  The 
immature virion acquires an envelope via budding through an intracellular membrane and 
is believed to be released from the cell through the secretory pathway to initiate another 
round of infection.8 An overview of the HCV lifecycle can be seen in Figure 1. 
Internal Ribosome Entry Site 
The internal ribosome entry site is the RNA structure that facilitates synthesis of 
the HCV polyprotein.  The IRES consists of 330 nucleotides in the 5’ UTR of the 
3approximately 9600-nucleotide viral genome, and it folds into a complex three-
dimensional structure with four characterized domains.  With a minimal subset of 
endogenous transcription cofactors, the IRES utilizes the host ribosomal machinery to 
produce the viral polyprotein.  In conventional eukaryotic translation, the 5’ 7meG-cap 
structure of the host mRNA assembles with eukaryotic initiation factor 4F (eIF4F).  This 
eIF4F complex is a heterotrimer consisting of eIF4E (the cap-binding subunit), eIF4A (an 
RNA-dependent ATPase/ATP-dependent RNA helicase), and eIF4G (a high molecular 
weight scaffold for eIF4E and eIF4A binding).  The eIF4F complex then serves as a 
scaffold for the recruitment of the 40S subunit, eIF1, eIF1a, the ternary complex (eIF2-
Met-tRNAiMet-GTP), eIF3 and eIF4B.  The eIF1 and eIF1A factors are thought to 
synergistically facilitate the proper formation of the 48S complex at the initiation codon, 
but they are not critical for simple complex formation.9 The eIF4B subunit is thought to 
facilitate the association of mRNA with the 40S subunit.10-12 This assembly then utilizes 
ATP hydrolysis to scan the 5’ UTR of the mRNA for the AUG start codon to form the 
transient 48S complex.  GTP hydrolysis in the ternary complex then triggers the release 
of initiator tRNA and the dissociation of eIF2 from the complex.  This is followed by 
another GTP hydrolysis event involving eIF5B that recruits the 60S subunit while also 
releasing eIF3 to form the 80S complex, which is then followed by peptide bond 
formation.13, 14
In contrast, IRES mediated translation initiation involves the binding of the IRES 
to the 40S subunit in the absence of several canonical eukaryotic initiation factors.  This 
complex then recruits eIF3 and the ternary complex to form a 48S-like complex that, like 
the normal 48S subunit, positions the AUG start codon of the IRES at the proper position 
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on the ribosome for initiation of translation, but without ATP hydrolysis dependent 
scanning.  Interestingly, the IRES is capable of specifically binding eIF3 independently 
of the other initiation factors.15 After the assembly of the 48S-like complex, translation 
occurs more or less conventionally.  As in host cap-dependent translation initiation, GTP 
hydrolysis facilitates the release of the initiator tRNA and the dissociation of eIF2 from 
the complex.  Also as in conventional translation, a second GTP hydrolysis event 
facilitated by eIF5B16 then releases eIF3 and concurrently recruits the 60S subunit, and 
viral polyprotein translation commences.  The eIF4B appears to play a similar role in 
both translational paths.17 Thus, structural motifs in the IRES and/or interactions between 
the IRES and the ribosome seemingly obviate the requirement for eIF1, eIF1a, eIF4F and 
5’-7meG capping in ribosomal translation.18-20 The differences between conventional 
eukaryotic translation and IRES translation are summarized in Table 1.      
Four domains (I-IV) of the IRES have been identified21 and characterized for 
activity.15 The complete secondary structure of the HCV IRES is shown in Figure 2.  
Domains II-IV have been shown to interact with the 40S subunit, and have been shown to 
be necessary for translation.15   Domains III and IV drive binding to the 40S subunit, and 
are independently capable of binding to the 40S subunit with a KD approaching that of the 
complete IRES.22 
Mutations of the apical loops of domain III negatively impact recruitment of eIF3 
and, subsequently, the ternary complex. This is consistent with cyro-EM studies that 
suggest extensive interactions between domain III and eIF3.23 Mutational studies also 
suggest that the basal region of domain III is responsible for tight binding to the 40S 
subunit.24, 25 
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Domain II is an independently folded extended duplex. The terminal half of 
the extended duplex is often referred to as domain IIb while the lower half is known as 
domain IIa.  Domain IIa possesses a 5 base bulge that introduces a significant bend in the 
structure.26-28 Mutational studies have shown than the deletion of this bulge region 
destroys IRES activity in vivo.29-31 A number of potential interactions between domain II 
and the ribosome have been reported.  The apical loop of domain II sits over the E site 
and closes off the mRNA cleft.31 The apical loop is believed to induce changes in 
ribosome conformation that are critical for translation,19 and it has been suggested that 
the loop may interact with the ribosomal protein S5 (rpS5) and thus impact positioning of  
the IRES on the 40S subunit during translation initiation.32 Other cross-linking studies 
have suggested interactions of the domain II apical loop with proteins S14 and S16 on the 
40S ribosomal subunit.18 The secondary structure and three-dimensional solution 
structure of the lower domain IIa region has been determined by Lukavsky et al27(Figure 
3).  
Deletion of domain II does not significantly impact 40S subunit binding affinity 
20, 22, 25 or recruitment of the ternary complex and eIF320; however, deletion does  reduce 
translation by five-fold by impeding 80S formation.15, 20, 24, 33 The Lukavsky group has 
suggested that this phenomenon is due to the fact that this domain (specifically the apical 
loop and the bulge region in domain IIa) is critical for eIF5 induced GTP hydrolysis and 
the subsequent release of eIF2 and GDP during the joining of the 60S ribosomal subunit 
to form the full 80S ribosome.  Deletion of the entire domain arrested ribosome assembly 
at the 48S stage as determined by sucrose gradient experiments,20 and the deletion also 
appeared to diminish 48S formation.  Three mutants involving deletion of the five base 
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bulge in domain IIa, the apical loop of domain II, and the loop E motif (a G bulge 
and proximal mismatches in domain IIb that result in an S shaped bend in the backbone, a 
common RNA structural motif) all inhibited 80S formation like that of the full domain II 
deletion mutant.30 
Spahn et al performed cyro-EM studies of the IRES RNA in complex with the 
ribosome.  They found that domain IIa was bent in complex with the ribosome in much 
the same manner as has been described for the free IRES.31  See Figure 4.  The HCV 
IRES IIa bend is conserved in IRES structures from different viruses even though the 
sequences involved in generating the “bends” are quite different.  The classical swine 
fever virus (CSFV) is known to have an IRES that is similar in structure and function to 
the IRES of HCV.  Interestingly, the apical loop, loop E motif, and a similar global bend 
are all present in the IRES of the classical swine fever virus.  The CSFV domain II 
structure has been shown to have a bend of 60.4± 9.1˚ compared to the HCV domain II 
with a 84.5 ± 9.6˚ bend.20, 27 See Figure 5.  This region in both viral genomes was shown 
to contain specific binding sites for divalent metals that provide stabilization of this 
motif.26 Pestova et al also concluded that, like the HCV IRES domain II, the CSFV IRES 
domain II is critical for inducing the conformation changes in the 48S complex that are 
necessary for eIF5-induced hydrolysis of the GTP in the ternary complex.  This step is 
necessary for disassembly of the 48S complex prior to 60S subunit recruitment.34 
 
Targeting RNA with Small Molecules 
 
 RNA has the unique ability to hold both genetic information in its base sequence 
and to fold into complex three-dimensional structures capable of catalysis or involvement 
in regulatory binding interactions with proteins, small molecules or other RNAs.   Thus, 
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RNA can be a therapeutic target in two different ways.  One approach is to attack 
RNA as a bearer of protein sequence information.  Antisense and siRNA drugs target 
RNA sequence as the basis for attack, and the therapeutic goal is the regulation of gene 
expression. 
The folding of RNA into complex three-dimensional structures with catalytic or 
regulatory functions presents the possibility of treating RNA targets in much the same 
way as protein targets.  That is, a key binding or catalytic domain in the RNA can be 
targeted with inhibitory small molecules.  The many unique structural motifs presented 
by the complex and diverse folding patterns of RNA can potentially afford both 
specificity and tight binding for small molecules.  See Figure 6.  The various bulges, 
loops, and junctions seen in RNA enable potential drugs to access both the minor groove 
and the typically less accessible major groove.  The therapeutic goal of this approach is to 
inhibit catalysis of a reaction or prevent some recognition or binding event from 
occurring.    
In practice, the binding of many RNA targeted drugs is thermodynamically driven 
by electrostatic interactions.35  Intercalating drugs also target nucleic acids (typically 
DNA) by interacting extensively with the bases and thus have a strong dipole-induced 
dipole packing component to their target-binding affinity.  In contrast, the binding of 
most protein-targeted drugs is thermodynamically driven by hydrophobic interactions 
between rigid, largely hydrophobic drugs and well defined hydrophobic binding sites on 
the protein.  
Typically, proteins can offer a broader variety of chemical environments due to 
the much larger list of conventionally encoded amino acids (20) compared to the four 
 8  
nucleotides that constitute RNA.  The extensive post-translational modifications 
seen in proteins provide still further chemical variation.  Post-transcriptional 
modifications in RNA provide some additional binding site diversity, but these are 
neither widespread nor especially diverse outside of tRNA.  Protein binding sites are also 
considered to be more static and well defined than the more flexible RNA targets.36 The 
study of RNA binding drugs is a developing field, and higher affinities and specificities 
may be achieved in the near future.   
 
Established RNA Targets 
 
The Ribosome   
The bacterial ribosome is the target of many RNA binding small molecule drugs.  
The large size of the ribosome, with its numerous functional sites and areas of interaction 
with tRNA, mRNA, and nascent peptides gives rise to a diversity of binding 
environments for small molecule inhibitors.  It is not surprising that ribosomal peptide 
synthesis is susceptible to such a broad variety of inhibitors operating by diverse 
mechanisms.  Many of the most successful, well-known, and widely used RNA binding 
therapeutics fall into this category.   
Aminoglycosides represent an important subcategory of ribosome-targeting drugs 
that interact with the 16S rRNA of the 30S subunit in the bacterial ribosome.  This class 
of drugs has been widely studied and is characterized by a 2-deoxystreptamine (2-DOS) 
core that drives binding.37  See Figure 7.  They effectively target prokaryotic ribosomal 
activity, but they often have low target affinity and specificity.  Due to their many basic 
amine groups, they are cationic at physiological pH, which is in some measure 
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responsible for their antimicrobial activity,38 but it can also make them very 
promiscuous binders to negatively charged RNA and other negatively charged cellular 
targets.  
The mechanism of action of paromomycin, a representative aminoglycoside, has 
been studied extensively.   Early NMR studies of paromomycin in complex with a model 
A site of the 16S rRNA suggested that the compound binds in the major groove of helix 
44.39, 40 These studies showed that Ring 1 of paromomycin inserts into the RNA helix and 
facilitates the flipping out of bases A1492 and A1493.  It also stacks on G1491 and 
hydrogen bonds to A1408.  Later crystal structures by the Ramakrishnan group 
corroborated the placement of the drug and yielded further insights into the specific 
mechanism of inhibition.41, 42  
The flipping out of bases A1492 and 1493 from the interior of helix 44 is key to 
the mechanism of inhibition.  Mutagenesis studies have revealed that ribosomal bases 
A1492 and A1493 are critical for A-site tRNA binding.43 Analogously to the 
paromomycin bound 30S structures, the crystal structure of the 30S subunit in the 
presence of a codon and cognate tRNA anticodon stem loop similarly shows A1492 and 
A1493 flipped out of helix 44.  However, in this context the two bases are involved in 
direct hydrogen bond contacts with the first two codon positions of the codon/anticodon 
interaction via the minor groove.  The placement of the two adenines in the minor groove 
is dependent on Watson-Crick base pairing of the first two codon bases.  Non-Watson-
Crick base pairs in these positions disrupt the geometry and hydrogen bonding of the base 
triple while still keeping the bases in close proximity.  This close proximity disallows the 
solvation of the exposed polar groups on the bases resulting in a large desolvation penalty 
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for near-cognate tRNA binding.  In contrast, cognate tRNA binding is 
thermodynamically favorable and results in a domain closure in the 30S subunit.42, 44 
Paromomycin fixes the flexible A1492 and A1493 nucleotides in a conformation 
like that induced by cognate tRNA, and thus decreases their entropy and subtly alters other 
structural aspects of the A site.  The result is that the energetic difference between cognate 
tRNA binding and near-cognate tRNA binding becomes much smaller.  This in turn 
facilitates closure of the 30S subunit in the presence of a near-cognate tRNA, which is 
typically disallowed in the absence of paromomycin.  This results in error prone 
translation.44  See Figure 8. 
Later crystal structures involving paromomycin, streptomycin and spectinomycin 
revealed further insights into general binding characteristics of this drug group as well as 
variations between different aminoglycosides and similar compound classes.  All three 
were found to interact with the 30S subunit.  Spectinomycin, an aminocyclitol antibiotic, 
inhibits translocation of the peptidyl-tRNA from the A-site to the P-site, while 
streptomycin, like paromomycin, disrupts proofreading and leads to error prone protein 
synthesis.  All three bind specifically through largely polar and electrostatic interactions.41   
Macrolides, such as erythromycin, are another category of antibiotics that target 
the ribosome.  This category of compounds typically binds in the polypeptide exit tunnel 
next to the peptidyl transferase center in the 50S subunit.  They are thought to inhibit 
translation by impeding the exit of nascent polypeptides from the ribosome.45, 46 
Chloramphenicol is a nonaminoglycosidic, nonmacrolide antibiotic known to 
disrupt peptidyl transferase activity. The crystal structure of the chloramphenicol bound to 
the large ribosomal subunit reveals that it binds in a hydrophobic crevice at the entrance to 
A 
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the peptide exit tunnel, perhaps acting analogously to the macrolide antibiotics.46, 47 
Puromycin is a 3'-aminoacyl tRNA mimetic that halts peptide chain elongation as it 
becomes incorporated into the nascent chain. 47 
Hansen et al have shown that many non-aminoglycosidic, non-macrolide 
antibiotics (specifically Anisomycin, Virginiamycin M, Sparsomycin, and Blasticidin S) 
bind to the 50S subunit in and around the peptidyl-tRNA or aminoacyl-tRNA binding sites 
and thus competitively inhibit peptide bond formation. 47 This leads to amino acid 
misincorporation.   
   Tetracycline, a nonaminoglycosidic antibiotic, also attacks translation by 
promiscuously binding in the A site of the 30S subunit to disrupt aminoacylated tRNA 
binding.48, 49 Pactamycin, another nonaminoglycosidic RNA binding drug, also inhibits 
ribosomal translation through binding in the E site of the 30S subunit.  It is thought to 
adopt a form on the ribosome in which two aromatic rings in the compound fold over one 
another to mimic a dinucleotide.  In this form, it displaces mRNA from its position in the 
E site.49 Viomycin, another nonaminoglycosidic drug, is known to inhibit translation by 
keeping the peptidyl-tRNA stuck in the A-site. A survey of representative ribosome 
binding drugs is shown in Figure 9. 
 
Tat/TAR   
In addition to the ribosome, there are many unique RNA targets in pathogens that 
can possibly be exploited with specificity due to the absence or extreme dissimilarity of 
analogous targets in humans.  RNA viruses and retroviruses offer especially compelling 
possibilities for such a targeting approach due to the unique and critical roles that RNA 
plays in their lifecycles.   
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The TAR element of HIV-1 is a highly promising and extensively studied 
RNA therapeutic target.  It is known to interact with the HIV-1 Tat protein, the 
transactivator of the HIV-1 LTR.  While there is currently no available therapeutic 
targeting this RNA, this is an area of active research.50, 51   
 
Internal Ribosome Entry Site   
Another interesting pathogenic RNA structural drug target is the IRES of 
picornaviruses and flaviviruses.  The IRES of the hepatitis C virus in particular has been 
studied extensively.  As described previously, this structure facilitates the utilization of 
host ribosomal machinery to translate viral proteins.  The unique role of this structure in 
the viral lifecycle makes it an appealing therapeutic target.  This complex three-
dimensional structure with its multiple points of interaction with the human ribosome 
offers a number of potential sites for inhibitory attack.2, 52  
There are currently no IRES targeted drugs in clinical use.  There have been 
studies on a number of potential HCV therapeutics including siRNAs53, and small 
molecules.54 The mechanism of action of these small molecule inhibitors in the work of 




Figure 1: HCV life cycle. Reprinted with permission from Suzuki et al (2007, Elsevier B.V.) 
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Figure 2: Full HCV IRES secondary structure.  Domains I-IV are labeled.  This figure is 
adapted from Fraser et al. (2007). 
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 Figure 3: The three-dimensional and secondary structures of domain IIa.  The 84.5º bend in the structure occurs at a five 










Figure 4: Cryo-EM structure of the HCV IRES bound to the ribosome.  The ribosome is not shown. Adapted from Spahn et al 
(2001).  Representation of a subset of A-form helices from the HCV IRES bound to the 40S subunit fit into the IRES surface 
generated through cryo-EM studies.  The green helix corresponds roughly to domain IIb while the blue helix corresponds 






Figure 5: Comparison of HCV and CSFV IRES structures.  Representations of the three dimensional and secondary 
structures of the IRES domain IIa constructs from the hepatitis C virus (A) and the classical swine fever virus (B).  Both 





            
            







Figure 6: Sample of RNA secondary structural motifs: (A) a stem loop; (B) a bulge; 
(C) an internal loop; (D) a single strand; (E) a four-way junction; (F) a duplex.   
   A                 B              C              D                        E                              F 



















































Figure 8: Influence of paromomycin on the A site of the 30S subunit.  A) The native 30S 
subunit with A1492 and A1493 stacked in the interior of helix 44.  B) Paromomycin binds 
in the A site and flips A1492 and A1493 out of helix 44 in a conformation like that shown 
in C.  C) A cognate tRNA ASL paired to an mRNA codon in the A site results in the 
flipping out of A1492 and A1493 to form base triples with the first two codon positions of 
the codon/anticodon interaction.  The stability and energetic favorability of this interaction 
is dependent on Watson Crick base pairing of the first two codon positions and thus serves 
to screen out near-cognate tRNA in the A site.  D) The binding of paromomycin to the 
30S subunit in the presence of the tRNA-ASL and the codon changes the structure very 
little compared to that shown in C.  Paromomycin stabilizes the interaction of the 30S 
subunit with near-cognate tRNA.  Thus, the energetic difference between the binding of 
cognate and near-cognate tRNA is minimized, and amino acid misincorporation is 
facilitated.  Reprinted with permission from Ogle et al (2001, AAAS). 
 
 
Figure 9: Sample of RNA targeted drugs known to target the ribosome.  Paromomycin and streptomycin are true aminoglycosides 
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Isis Pharmaceuticals, Inc. graciously provided us with milligram quantities of a 
lead compound described as compound 11 in the published account, hereafter described 
as Isis-11 (Figure 10).
54
 This compound was developed from a KD = 100 uM 
benzimidazole “hit” from a 180,000 member library screened through a mass 
spectrometry based method.  A "hit" was required to have a KD of l00 µM or less with a 
29-mer HCV IRES domain IIa RNA construct, and that KD had to be three fold lower 
than that of the "hit" with a 33-mer structured RNA control.  Thus, a "hit" had to bind 
both tightly and specifically.   
Employing a mass spectrometry-based method, Isis-11 was determined by Isis to 
bind to the IRES construct with a KD of approximately 0.86 µM.  Fluorescence data 
collected in our lab suggested a KD of approximately 2 µM.  The slight difference in KD 
numbers could be attributable to the differing experimental approaches used, or to 
experimental uncertainty.   
In a cellular HCV replicon assay, Isis-11 was found to inhibit the production of 
viral RNA with an EC50 of 3.9 µM.  The comparable RNA binding constants and in vivo  
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activities for this molecule and others in the same chemical class suggest that the binding 
of the specific RNA target is the mechanism of viral replication inhibition. 
The potential exists for up to three positive charges on the compound.  The two 
tertiary amines are both likely to be charged at the pH 6-7 range, as the pKas would be 9-
10.  The primary amine on the ring, by analogy to other known structures, is assumed to 
have a pKa of approximately 6-7.  Thus, this amine may also be charged under the 
solution conditions we employed.  Modeling of the molecule in the binding site was done 
under the assumption that all three of these amines are positively charged at the pH of the 
experimental samples (pH 7). 
The positive charges on these amines could lead to non-specific ionic or hydrogen 
bonding interactions with the negatively charged RNA; however, synthetic variations on 
Isis-3 (another benzimidazole compound from Isis that also contained the 2-amino group 
and two tertiary amines on methylene tethers) suggest that the charged groups interact in 
a specific manner at the binding site.54   See Figure 11.  A synthetic variant of Isis-3 that 
lacked the 2-amino group (Isis-7) showed a greater than 10-fold affinity decrease from 
Isis-3.  A variant that lacked the methylene arm and tertiary amine at the N1 position 
(Isis-8) showed a similar decrease.  Isis-9, which displaces the other arm without 
eliminating it, similarly had lower affinity.   
Our collaborators at Isis used mass spectrometry based footprinting assays to 
localize binding of Isis-11 and analogous compounds in specific IRES constructs.  
Inhibitors were found to interact with bases in and around the adenosine-rich five base 
bulge which has been shown to be critical to the overall shape of domain II.54 This 
compound was shown to bind to constructs that favored both the published IRES domain 
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II structure 27 and an alternate secondary structure previously proposed by the Doudna 
group.55 
It is interesting to note that the compound could bind with similar affinity to 
different constructs with differing secondary structures. It is still unclear what this means 
as there is no published structure of any constructs biased to adopt the Doudna form.  It is 
possible that the structure at the locus of binding is similar in either case.  The portion of 
the secondary structure previously proposed by the Doudna group pertinent to the binding 
site of Isis-11 is approximated by the IRES2 construct shown in Figure 12. 
 
Isis-11 NMR Assignments 
In order to determine the structure of Isis-11 in complex with the IRES, it was 
first necessary to establish intermolecular distance restraints between Isis-11 protons and 
IRES protons as determined by Nuclear Overhauser Effect interactions.  Thus, it was 
necessary to determine the 1H chemical shifts of the Isis-11 protons.  In order to do that, 
it was also necessary to determine the 13C chemical shifts.  The inhibitor proton 
assignments were established using TOCSY, ROESY, and HMQC/HMBC NMR 
experiments for a 1 mM Isis-11 sample dissolved in D2O.  The lone chiral proton 
provided an unambiguous starting point to connect protons on the furan chain by TOCSY 
connectivity.  The methylene TOCSY connectivities for the long chain established those 
assignments, and the crucial distinction of the two dimethylamino methyl groups was 
made by ROE connectivity to protons on the relevant methylene chains.  The two protons 
on the aromatic ring were assigned by HMBC connectivity to ring carbons.  The Isis-11 
chemical shifts are unchanged at 7-fold excess to the IRES target, as expected for a 
system in fast-dominated exchange.  NOESY and ROESY NMR experiments established 
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that Isis-11 binds in an extended conformation; intramolecular NOEs were negative, 
consistent with cross-relaxation by the bound form. 
  The 1H and 13C NMR resonance assignments are shown in Figure 13.  All Isis-
11 assignment experiments were conducted on a Varian MERCURY 400 MHz and 
Varian INOVA 500 instruments at the University of Utah, which are well suited to small







A gravimetric approach was used to quantify Isis-11.  The synthesis product as 
provided to us contained an excess of acetic acid and acetate salts.  The amount of acetic 
acid relative to Isis-11 was estimated based on NMR peak intensities, and the 
concentration of our solutions adjusted accordingly.  There was some variability in 
compound concentration from sample to sample, but all of the NMR samples possessed 
Isis-11 at roughly a 7- to 9-fold excess to the IRES construct based on peak intensity 
comparison to the resolved peaks in the spectra from added spermine.  The RNA 
chemical shifts were very consistent between the different complex samples with excess 




The IRES5 RNA construct was developed in order to satisfy several requirements 
presented by this system.  Firstly, it was necessary to incorporate all of what was believed 
to be the relevant binding region of the IRES domain IIa.  Secondly, it was necessary to 
include a relatively long stem and a stable hairpin tetraloop at each end of the construct in 
order to limit possible destabilization and unfolding of the RNA upon compound binding 
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in the bulge.  However, the construct should be as small as possible while meeting the 
other requirements in order to limit spectral complexity and the line broadening that 
accompanies high molecular weight.   
To these ends, smaller constructs (IRES2 and IRES3) were used in early titration 
experiments.  IRES2 appeared to bind well to Isis-11, but it did not assume the secondary 
structure of the published solution
27
 and crystal structures
26
 but rather adopted a 
secondary structure postulated by the Doudna group prior to the publication of the NMR 
and crystal structures.
55
   IRES3 assumed a secondary structure like that of the published 
account, 
27
 but predicted free energy calculations in mfold showed it was also capable of 
assuming the Doudna structure with a low thermodynamic penalty.  In practice, IRES3 
was destabilized upon compound binding.  The IRES4 construct showed promise, but it 
was abandoned for the slightly smaller IRES5 when it was shown that most of the long 
upper stem was left unperturbed by Isis-11 binding and thus was probably irrelevant to 
our study.  While it is possible that IRES5 could be further minimized and still form an 
adequately stable complex with the compound, no further construct minimization was 
pursued for the determination of this structure.  Figure 14 shows the IRES5 construct 








   
Initial work was conducted on a 400 µM IRES5 sample with 25 mM KCl, 25 mM 
NaCl, and 10 mM sodium phosphate at pH 7.0.  These conditions were suitable for the 
free IRES5 at a range of temperatures (10-30º C).  Addition of low, sub-stoichiometric 
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amounts of Isis-11 (~1/10 RNA concentration) led to line broadening of a small subset of 
peaks; however, addition of higher amounts of Isis-11 led to heavy, global line 
broadening of all NMR peaks even at higher temperatures (>30º C).  For example, 
13
CHSQC spectra were uninterpretable due to the lack of any distinct, resolved cross 
peaks.      
We hypothesized that the positive charges on the Isis-11 could lead to non-
specific interactions with the negatively charged phosphate backbone of the RNA, 
especially in low salt conditions.  I attempted to correct this problem with spermine.  As a 
positively charged polyamine, spermine could compete out these nonspecific interactions.  
This approach showed some promise in titrations that were followed by monitoring 
changes in the imino region of the 
1
H spectrum; however, spermine addition was not 
sufficient to correct the line-broadening problem in the 
13
C HSQC experiments.  
Ultimately, all of the relevant data were collected in samples with 2 mM spermine based 
on the observation that spermine appeared to partly compete out weak, non-specific 
interactions between Isis-11 and the RNA as indicated by the improvement in the imino 
NMR spectrum.  The addition of spermine alone did not cause any significant line 
broadening or changes in the spectra. 
Increasing concentrations of KCl and NaCl were found to significantly diminish 
the line broadening caused by nonspecific Isis-11 binding.  While the 
13
C HSQC cross 
peaks were still broader in the complex than in the free RNA, the catastrophic line-
broadening problem seen under low salt conditions was mitigated.  Ultimately, the data 
pertinent to the complex structure determination were collected from samples containing 
both 150 mM NaCl and 150 mM KCl.  Under these conditions, the non-specific line 
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broadening was minimized even at high molar excesses of Isis-11.  The efficacy of 
monovalent salts in competing out the nonspecific compound binding suggests that the 
electrostatic interaction of the positively charged amine groups of Isis-11 with the 
negatively charged phosphate backbone of the RNA is the driving force behind the non-
specific binding.      
 The high salt, high spermine conditions employed in these experiments represent 
a very potent means of competing out nonspecific, electrostatically driven interactions.  
These conditions could be generally useful in the screening of charged drug candidates 
against RNA.  Indiscriminate binding of positively charged compounds to RNA can 
create false leads in drug discovery.  High salt concentrations can effectively shield the 
negative charge on the backbone and thus eliminate or greatly reduce nonspecific 
binding.  These conditions also represent a closer approximation of physiological 
conditions than is the case in a low salt NMR buffer.   
Magnesium is known to interact specifically with domain II of the IRES.  Free 
IRES5 had a slightly different imino spectrum in the presence and absence of 
magnesium.  Addition of magnesium caused U12 and G33 to move downfield and 
upfield respectively.  The free IRES5 also showed some differences in the aromatic 
13
C 
HSQC spectrum in the presence and absence of Mg
2+
.    
Magnesium was not included in our complex study experiments because the Mg
2+
 
appeared to slightly exacerbate the already extant line broadening problems.  This may 
have been due to exchange phenomena caused by magnesium ions competing for the 
binding site of the compound as both the binding site of the molecule and at least two 
specific Mg
2+
 binding sites overlap.  Alternatively, it could also be due to some degree of 
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RNA aggregation facilitated by divalent ion binding, or possibly due to intermediate 




 Regardless of the mechanism of the line 
broadening, Mg
2+
 was omitted to improve line widths.  
While the presence of Mg
2+
 changes the imino spectrum of the free RNA, the 
imino spectrum of the complex looked essentially the same in the presence and absence 
of Mg
2+
.  See Figure 15.  The fact that the imino spectra look the same in the presence 
and absence of magnesium lends credence to a model in which the compound interacts 
with portions of the IRES domain that are key magnesium binding domains and thus 
disrupts or out-competes magnesium binding.  Also, RDC experiments on the free IRES5 
under our conditions suggested that our construct adopted essentially the same fold and 
bend as the published structure that included magnesium.  Thus, the changes in the 
structure of IRES5 in the complex are attributable to Isis-11 and not to the absence of 
magnesium.  
Proper folding of the free IRES5 was sensitive to pH.  Three 100 µM IRES5 
samples were made in 25 mM KCl, 25 mM NaCl, 10% D2O and 10 mM Sodium 
phosphate at pH 7, 6.4, and 5.5.  The samples were then annealed in 5 mM Shigemi NMR 
tubes by placing them in a 150 mL beaker of boiling water which was subsequently 
allowed to come to room temperature.  The samples at pH 7 and 6.4 annealed properly as 
evidenced by the imino spectra while the pH 5.5 sample misfolded.  It is not clear if this 
is due to duplex formation or some other misfolding or aggregation problem.  
Nevertheless, due to this manifest pH sensitivity, the data used for structure 
determination were collected on samples buffered at a pH of 7.0.   
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 The IRES5 construct was poorly behaved at concentrations higher than ~450 µM.  
At slightly higher concentrations, the imino spectrum peaks begin to broaden and run 
together.  At very high concentrations (>600 M), the spectrum becomes similar to the 
dilute sample spectrum, but the upfield tetraloop G peak is missing.  This concentration 
dependent sample behavior is consistent with duplex formation.  The NMR experiments 
conducted in this study were performed on samples with RNA concentrations of 400 µM 
or less.  Of these, some of the more highly concentrated samples had artifact peaks that 
were absent or weaker in less concentrated samples.  These artifact peaks were not 
shifted or broadened by compound binding.  These peaks can be summarized as follows: 
At higher concentrations, there were two artifact C6-H6 cytosine peaks seen in the 
aromatic 
13
C HSQC.  There was one strong adenosine C8-H8 and one strong adenosine 
C2-H2 peak at higher concentrations.  There was another very weak adenosine C8-H8 
artifact peak as well.  There was also one guanosine C8-H8 artifact peak.  There were no 
substantive uridine artifact peaks.   
At higher concentrations (800 uM), the G23 C8-H8 cross peak from the 
13
C 
HSQC spectrum disappears completely from its usual place location while the rest of the 
spectrum changed little.  If the high concentration sample is truly an extended duplex, 
then the domain IIa five base bulge region should be identical to that seen in the hairpin, 
but multiplied by two for each duplex dimer.  Thus, the duplex dimer should behave like 
the monomer hairpin with respect to compound binding, which occurs far away from the 
tetraloop.  Obviously, this situation is not acceptable for some experiments; however, 
some of this data is usable for looking at changes around the binding site, which should 
be intact.  Some early 
13
C HSQC titrations experiments on a 800 uM sample will be 
 31 
 
referred to in this dissertation as they relate to line broadening at low stoichiometric 
equivalents of the compound, but all of the other data used for this study were generated 
from samples of lower concentration to avoid duplex formation. 
   
RNA Production   





labeled nucleotide triphosphates purchased from either Isotec or Cambridge Isotope 




N labeled nucleotide triphosphates purchased from Sigma 
Aldrich, Acros Organics, and MP Biomedicals.  Single stranded DNA oligonucleotides 
were purchased from the peptide/oligonucleotide synthesis facility at the University of 
Utah.  These were made with 2' O-Me at the two terminal 5' bases to facilitate the 
synthesis of homogeneous RNA transcipts.
57, 58
 An optimized T7 RNA polymerase 
promoter sequence was placed upstream of the RNA coding sequence and a 
complementary DNA primer was annealed to the template DNA in 10 mM Tris-HCl pH 
7.5 and 10 mM MgCl2 buffer at 95º C for 1-3 minutes, depending on volume.  This 
solution was then diluted 8 fold with the same annealing buffer listed above for a final 
concentration of about 1.8 µM template and 2.7 µM primer.  
 A solution was made with rNTPs at 6.5 mM each, 43 mM MgCl2, 7 % 
RNAsecure (v/v) from Ambion, and then incubated at 65º C for 10 minutes to activate 
the RNAsecure, and then cooled for 20 minutes at room temperature as per the 
manufacturer's instructions.  Subsequently, the solutions were incubated at 37º C for 5 
minutes before adding the annealed DNA and the T7 polymerase enzyme.  The annealed 
DNA is highly diluted and is added in a large aqueous volume effectively diluting the 
above listed concentrations by approximately 1.5 fold.   The T7 polymerase was added in 
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excess compared to typical published or supplier recommended concentrations because 
this marginally improved reaction yields.  Typically, the enzyme was added to a final 
concentration of 0.25 mg/mL by adding 50 µL of 5 mg/mL T7 polymerase per 1 mL 
reaction.  Reactions were allowed to proceed for a minimum of 4 hours.  Once substantial 
precipitation was visible in the tube, the reaction had usually gone to completion with 
high yields.  
The RNA was purified by ion exchange chromatography employing a column 
packed with Pharmacia (Amersham) Source Q support, eluting with a gradient of LiClO4.  
Buffer A consisted of 20 mM LiClO4 and 20 mM ammonium acetate with 5% 
acetonitrile.  Buffer B consisted of 600 mM LiClO4 and 20 mM ammonium acetate with 
5% acetonitrile.  The gradient employed went from 0 to 50% B over 20 minutes.  The 
column was heated to 50º C.  The latest eluting large peak is usually the full length RNA, 
as the ion exchange column binds RNA oligonucleotides of longer length with higher 
affinity.  The full length RNA is usually well resolved from the unincorporated rNTPs 
and short early termination transcripts.  The appropriate fractions were pooled and then 
dialyzed (Spectrum 1000 MWCO) against water (1 x 2L), 0.5 mM EDTA (1 x 1L), 0.5 M 
NaCl (1 x 1L), and finally 3 x 2 L water.  The purified samples were lyophilized and then 
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Figure 10: Structure of Isis-11 from Isis Pharmaceuticals.  
Figure 11: Specificity of benzimidazole binding.  Synthetic variations that eliminate or 
displace key amine groups have a deleterious effect on binding affinity.  Adapted from 









Figure 12: IRES constructs.  Various IRES domain IIa constructs used in NMR 





C assignments for the free Isis-11 
 
Figure 14: Secondary structure of the IRES5 construct and the full HCV IRES domain II.  The 
base numbering in the figure will be referenced throughout this dissertation.  The red uridine 
was omitted from our construct for stability and so does not have a number.  The green bases 
were added to stabilize the construct. 
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Figure 15: 1H Imino spectra with an excess of Isis-11 in the presence and absence of magnesium.  The common sample conditions 
were as follows: 230 µM IRES5, 150 mM NaCl, 150 mM KCl, 2 mM spermine, 10 mM sodium phosphate, pH 7.0, 20º C.  The 















All NMR data used to determine the complex structure were produced on Varian 
INOVA 500 and 600 MHz instruments at the University of Utah.  Some additional 
experiments were conducted on a Varian INOVA 800 MHz instrument at the University 
of Colorado at Boulder, but the line broadening in the complex was extreme at high field. 
The assignment of resonances for this structure was greatly facilitated by the 
previously published work of the Puglisi lab in the determination of the complete 
structure of the HCV IRES domain II.27 Our smaller domain IIa construct (38 residues vs. 
55 residues) and differing NMR solution conditions (Ours: 150 mM KCl, NaCl; 2 mM 
spermine; 10 mM sodium phosphate, pH 7.0.  Theirs: 100 mM NaCl, 5 mM MgCl2, 10 
mM sodium phosphate, pH 6.4) nevertheless yielded free RNA chemical shifts very 
similar to the published data. 
 
Imino Proton Data   
The imino protons on uracil and guanine provide simple data that are extremely 
powerful in the determination of RNA structure.  In a stable base pair, these protons are 
shielded from solvent exchange to the extent that strong signals can be seen in a 1H 
 38 
 
spectrum.  The chemical shift range of the imino protons is wide (~14-9 ppm).  AU and 
GC base pairs tend to occupy distinct regions of this range with some overlap while non-
canonical base pair interactions often have highly distinctive imino chemical shifts 
separate from the Watson-Crick pairings.  Consecutive base pair imino protons fall 
within 5Å and produce an NOE interaction.  Thus, a 2D NOESY can be run in H2O to 
provide data that can then be used to assign the imino spectrum.  This process is greatly 
facilitated by foreknowledge of the likely secondary structure of the RNA which can be 
predicted reliably for small, simple constructs with programs such as mfold.
59
 
 The free IRES5 provided narrow lines with high signal to noise in the imino 
spectrum, and we were able to assign this region with a 2D NOESY in H2O.
60
 In the 
complex, however, the line broadening reduced the signal to noise such that a 2D 
NOESY on the imino region was impractical.  Instead, 1D difference NOE experiments 
were run on an unlabeled complex sample to establish connectivity between adjacent 
imino protons.
61
 Imino peaks for uridine and guanosine were distinguished based on the 
15
N shifts measured from 
15








Carbon Bound Protons and NOESY Data.   
In order to determine a high resolution structure of the complex, it was necessary 
to choose a suite of NMR experiments that would enable us to detect and assign 
intermolecular NOE cross peaks within the context of the limitations of our system.  We 
were limited in the concentrations of RNA that could be properly folded.  We were also 
limited in the temperature range.  Lower temperatures, which under ideal circumstances 
might have enabled us to drive certain exchanges from the intermediate to the slow 
exchange regime, proved difficult to work with due to line broadening.  This may have 
 39 
 
been due to increased non-specific interactions, or it may have driven certain exchange 
rates farther into the intermediate range.  Thus, all NMR experiments, with the exception 
of the aligned RDC experiments discussed later, were performed at 35º C. 
 Line broadening in the complex, coupled with the high level of resonance overlap 
due to the high molecular weight of the RNA, made it necessary to employ NMR 
experiments that could provide us with adequate resolution.  One possibility was the use 
of 3D 
13
C HSQC filtered NOESY experiments.  This is the standard approach with 
proteins.  It is often used for RNA, but there are disadvantages.  Dispersion in both the 
sugar and aromatic regions are much poorer in RNA than in proteins.
63
 Chemical shift 
anisotropy also leads to faster T2 relaxation times and consequently broader lines than 
are found in proteins of similar molecular weight.
64
 Additionally, the inter-proton 
distances in RNA are typically longer on average than in proteins due to the lower 
density of protons per residue, especially outside of the sugar region.  Thus we have less 
signal and broader lines in a less dispersed spectrum.  In addition to these general 
difficulties, the concentration limitations and the exchange broadening in the IRES5/Isis-
11 complex made most 3D experiments impractical.   
 
Filter-Edit Experiments 
The challenges presented by the IRES5/Isis-11 complex were overcome through 
the use of a suite of filtered/edited NOESY experiments described by Feigon et al
65
 with 
selective isotopic labeling.  Selective labeling is the use of specific 
13
C labeled and 
unlabeled nucleotide triphosphates in one T7 transcription reaction in order to produce a 
sample that contains, for instance, 
13
C labeled guanosines and cytosines and unlabeled 
adenosines and uridines.  Such a sample can be used to produce 2D filtered/edited 
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NOESY experiments that are considerably easier to interpret than conventional 2D 
NOESY data produced on an unlabeled sample.  These experiments are also more 
sensitive than a 3D 
13
C HSQC filtered NOESY. 
 The term "filter" is used to describe a purge element that abolishes the signal from 
protons bound to an isotopically labeled nucleus (labeled protons) while retaining signal 
from protons bound to an unlabeled nucleus (unlabeled protons).  The term "edit" refers 
to a purge element that removes the signal from unlabeled protons while keeping signal 
from labeled protons.  Filtered/edited experiments work by applying either a filter or an 
edit before either the t1 or t2 evolution periods.    
Filter/edit NOESY experiments are often used with complexes involving a labeled 
and unlabeled component.  Such experiments can greatly facilitate the distinction of 
intramolecular NOE cross peaks from intermolecular NOE cross peaks while also sorting 
out the intramolecular NOE cross peaks from one complex component from the 
intramolecular NOE cross peaks from another complex component.  With a selectively 
labeled RNA, these experiments can be used to greatly simplify intramolecular NOESY 
data.  They are especially useful in assigning the highly congested aromatic to H1' and 
aromatic to H2'-H5" walk regions in RNA.  Three powerful filter/edit experiments were 
employed that resulted in relatively simple NMR spectra, facilitating resonance 
assignments.   
The F1 edit F2 edit (F1eF2e) experiment applies an edit before the t1 and the t2 
evolution periods, thus removing all NOE interactions from 
12
C bound protons as well as 
all NOE cross peaks to 
12
C bound protons.  Thus, the resulting NOESY spectrum 
contains only NOE cross peaks from 
13
C bound protons to 
13
C bound protons.  The H1' to 
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aromatic and H2'-H5" to aromatic walk regions of such a spectrum thus contains only the 
intranucleotide NOE cross peaks of the 
13
C labeled bases in addition to the 
internucleotide NOE cross peaks between labeled bases.  The 4D-
13
C-edited NOESY 
described by Vuister et al was run as a 2D experiment to generate these spectra.
66
 
 The F1 filter F2 filter (F1fF2f) experiment applies a filter before the t1 and t2 
evolution periods and thus filters out all NOE interactions from 
13
C bound protons as well 
as all NOE cross peaks to 
13
C bound protons.  The resulting NOESY spectrum contains 
only NOE cross peaks from 
12
C bound protons to 
12
C bound protons.  The spectrum 
contains only the intranucleotide NOE interactions of the unlabeled nucleotides as well as 
the internucleotide NOE cross peaks between unlabeled nucleotides.  An additional 
advantage of this experiment compared to the other filter/edit experiments is that there is 
less line broadening and signal loss from 
12
C bound protons than that from bound 
13
C 
bound protons.  Proton relaxation and the associated signal decay are thus slower in this 
experiment.  In practice, this proved to be a highly sensitive and informative experiment.  
The pulse sequence used in this study parallels that described by Zwahlen et al.
67
 
Additionally, the F1fF2f data sets facilitated intermolecular NOE assignments.  
Intermolecular NOE cross peaks seen in the F1fF2f spectrum from the AU labeled 
sample indicated interactions between G or C nucleosides with Isis-11.  Conversely, cross 
peaks seen in this experiment with the GC labeled sample were indicative of interactions 
between Isis-11 and A or U nucleosides.   
 The third experiment that completes this picture is the F1 filter F2 edit, or F1fF2e 
experiment.  This experiment employs a filter prior to the t1 evolution period and an edit 
prior to the t2 evolution period.  Thus, the f1 dimension contains only cross peaks from 
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unlabeled protons while the f2 dimension contains only cross peaks to labeled protons.  
This experiment filters out NOE cross peaks from 13C bound protons and then edits out 
all NOE cross peaks to 12C bound protons.  Thus, this spectrum contains only cross peaks 
from 12C bound protons to 13C bound protons (i.e., cross peaks only between unlabeled 
and labeled nucleotides).  The two halves of the spectrum on opposite sides of the 
diagonal offer unique information as well.  For instance, in the aromatic to H1' NOESY 
walk region, one side will contain cross peaks between labeled sugar protons and 
unlabeled base protons while the other side will contain cross peaks between labeled base 
protons and unlabeled sugar protons.  Thus, the spectral overlap is cut in half over and 
above the decrease in overlap from the removal of all labeled to labeled and unlabeled to 
unlabeled cross peaks.  Another advantage of this experiment is that it removes all of the 
very intense and comparatively uninformative pyrimidine H5-H6 cross peaks from the 
H6/H8 to H1' aromatic walk portion of the spectrum.  These spectra should be the least 
congested and the easiest to interpret.  The pulse sequence used for these experiments 
parallels that described by Stuart et al.68 
The F1fF2e can also be used with either a selectively 13C labeled or fully labeled 
RNA construct to look for NOE cross peaks between the unlabeled Isis-11 and the RNA.  
With a fully 13C labeled RNA construct, all of the NOE cross peaks in the spectrum will 
be intermolecular.  As this interface is the most interesting part of this structure, the 
advantages of such a data set speak for themselves.  All strong NOE cross peaks between 
the compound and the RNA were corroborated with this data set; however, in practice, 
the experiment was not sufficiently sensitive to see all intermolecular NOE cross peaks.  
Nevertheless, it was very helpful in locating medium to strong intermolecular NOE cross 
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peaks that were located in areas of the spectrum that were highly congested with 
intramolecular RNA cross peaks in the other NOESY experiments.   
 Combined, the three NOESY experiments described above contain all of the same 
NOE cross peaks as a conventional NOESY.  See figure 16.  In our experience, the signal 
to noise on the F1eF2e was very poor in comparison to the F1fF2e and the F1fF2f.  A 
more fruitful approach was to conduct the F1fF2f experiment on both a selectively AU 
labeled and GC labeled RNA sample.  An F1fF2f experiment on an AU labeled sample 
provides the same spectrum as an F1eF2e experiment on a GC labeled sample but with 
higher sensitivity.  The F1fF2f experiment was also conducted on GU, GA and GUA 
labeled samples in order to clear up some remaining ambiguities from the other data sets. 
 
Assignments 
Titrations of IRES5 with Isis-11 enabled me to follow changes in the 13C HSQC 
spectrum upon compound binding.  Some resonances were broadened at very low 
stoichiometric equivalents of compound.  In high salt, the overall quality of spectra is at 
its poorest at ~1 equivalent of Isis-11.  As the Isis-11 compound is titrated to excess, the 
peak shapes begin to improve.  Many of the broadened resonance peaks began to 
narrow at higher equivalents of compound.  Some resonances moved gradually as more 
compound was added.  Some resonances did not move at all.  The resonances that did 
not move served as a convenient starting point for the assignment of the bound RNA.  
Many of the intrastrand NOE connectivities were retained.  The resonances that were 
heavily broadened by exchange and then narrowed again at new chemical shifts were 
assigned based on connectivities to other known resonances.  These titration experiments 
were conducted on a selectively GC labeled and a selectively AU labeled RNA sample in 
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addition to a fully labeled sample.  The selectively labeled samples greatly facilitated the 
assignment and monitoring of changes in the pyrimidines as these protons have less 
dispersion in general and there are more pyrimidines than purines in the IRES5 construct. 
Two-dimensional filter/edit NOESY spectra were used in conjunction with two-
dimensional unlabeled NOESY data and 
13
C HSQC data to make definitive H1' to H8/H6 
walk assignments.  The intraresidue H1' to H8/H6 correlations were confirmed as much 
as possible with HCN experiments, although this data was of poor quality with our 
complex samples.  The NOESY data and 
13
C HSQC also facilitated determination of the 
H5 and H2 assignments on the pyrimidines and adenines respectively.  Further sugar 
assignments were determined using the two-dimensional unlabeled NOESY data in 
conjunction with HCCH COSY and HCCH Relay-COSY experiments.
69
 This enabled the 
assignment of most of the H2' and H3' sugar protons.  Short mixing time NOESY 
experiments also facilitated H2' and H3' assignments due to the fact that A-form helical 
RNA usually results in very short distances between n H2' protons and n+1 H6/H8 
protons in addition to intraresidue H3' to H8/H6 protons in A-form or nearly A-form 
regions. 
Due to line broadening, it was difficult to assign many NOE cross peaks in certain 
congested regions of the NOESY spectrum.  For this reason, and the limited sensitivity of 
the HCCH-RELAY COSY, the H5', H5'', H4', and H3' assignments are incomplete.  This 
left us with NOE cross peaks heavily weighted toward H1', H2', and H3' to aromatic, and 
aromatic-to-aromatic interactions.   
A handful of H4' and H5' and H5'' complex assignments were made on the basis 
of the Puglisi structure assignments.
27
 If the other resonance assignments for a given 
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residue did not change much upon compound addition, and if there was adequate 
resolution in the sugar region, then assignments were made for H4', H5', and H5'' 
assuming that they very closely matched the Puglisi assignments.  This was corroborated 
by filter/edit NOESY data.  
   
Residual Dipolar Couplings 
1
J C-H and N-H dipolar couplings are usually averaged out to zero due to 
isotropic tumbling of a molecule in solution.  In a weakly aligned molecule, the dipolar 
couplings can be large enough to measure.  A number of these can be used to calculate an 
order tensor frame.  Individual bond vectors are then fit into this order tensor frame to 
minimize the difference between the theoretical and the measured couplings in 
conjunction with other restraints.
70
   
The measurement of RDCs has become an important NMR method for 
determining macromolecular global structures and is especially powerful for positioning 
distal domains relative to each other.
27, 71-73
  As all of the other typical NMR restraints 
(i.e. NOE restraints, dihedral angle restraints, base pairing restraints) are short range in 
nature, it is necessary to support these restraints with global structural information in 
order to attain good global structural convergence.  
RDCs can be measured in a number of ways.  Experimental methods fall into one 
of two categories: intensity based methods and frequency based methods.  Intensity based 
methods are more prone to systematic errors than frequency based methods.
70
 The 
primary drawback to frequency based methods is the greater spectral congestion in 
coupled spectra, but this can be neutralized through the right choice of experiments.
70
 
The best approach for the measurements of RDCs in this system was through the use of 
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in-phase anti-phase (IPAP) experiments.
74-76
 The IPAP produces spin-state separated 
spectra within a single experiment.  In this experiment, two spectra are collected in which 
the coupling evolves either in phase or anti-phase.  These spectra are then added or 
subtracted to produce two spectra, each containing one half of the doublet.
74
 This 
minimizes spectral congestion.  
 The alignment media consisted of a C12E5/hexanol mix that has been shown to 
create a dilute nonionic liquid crystalline media ideal for weak alignment.
77
 The C12E5 
term describes an alkyl-poly(ethylene glycol) molecule with 12 carbons in the alkyl 
moiety and 5 glycol units comprising the poly(ethylene glycol).  RDC restraints for the 
aromatic protons were determined through the use of this alignment media at 3-3.2%.  
The optimal temperature for our alignment regime was found to be 31º C.  This is lower 
than the optimal temperature of 35º C used for all of our other nonexchangeable proton 
NMR experiments, but there was no significant peak movement when decreasing the 
temperature from 35º C to 31º C.  The cross peaks were broader for the aligned samples, 
probably due to a combination of additional exchange broadening at the lower 
temperature and the line broadening induced by the partial alignment.   
The alignment and lower temperature-induced line broadening, coupled with the 
already congested spectra under ideal conditions necessitated the use of AU and GC 
selectively labeled samples.  The AU and GC labeled samples were analyzed by 
13
C 
HSQC-IPAP with either C6 or C5 band-selective WURST decoupling in order to 
determine the aromatic C-H couplings.  HCCH-COSY-IPAP experiments with band 
selective WURST decoupling of the C2' carbons were used to measure the couplings for 





C HSQC spectra.  Some additional couplings were obtained exclusively 
from these coupled experiments due to superior peak shape and intensity in some cases.  
Additionally, imino N-H couplings were measured from coupled 
15
N HSQC spectra. 
Extensive overlap and line broadening prevented the complete determination of 
the C6-H6 couplings of the cytosines; however, the C8-H8, C6-H6, and C2-H2 couplings 
of the adenosines, uridines, and guanosines were sufficiently resolved.  Only four C5-H5 
couplings were measured due to poor spectral quality.  The error in our measurements 
was greater than the typical variability of the C-H coupling for unaligned RNA (<1 Hz).  
The unaligned values for the C2-H2, C6-H6, C5-H5, and C8-H8 bond vectors used to 
subtract from the aligned values were based on the measurements of Boisbouvier et al
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since it has been shown that the unaligned coupling values do not vary significantly for 
the aromatic bond vectors of a particular base type. 
The HCCH-COSY-IPAP experiments performed on these samples to determine 
the couplings on the C1'-H1' bond vectors proved to be the most challenging.  It was 
necessary to determine the aligned and unaligned RDCs for these bonds due to the fact 
the unaligned values vary greatly depending on the torsional angles of the sugars.  This 
compounded the sensitivity problem in that the peaks had to be strong, well shaped, and 
well resolved enough in four different spectra (aligned vs. unaligned, in phase vs. 
antiphase) in order to measure the RDCs for these bond vectors.  Due to these 
complications, only nine C1'-H1' RDCs were measured.  
In all cases, measurements were not included in the structure calculation if the 
peak was broadened to the point that it was not possible to locate the peak center with 




While there are many degrees of freedom in a free ribose ring, the classical A 
form helix typical of an RNA duplex forces the sugar into a very narrow range of 
possible conformations.  The sugar typically assumes a C3'-endo conformation under 
these circumstances.  The steric restraints placed on the ring by the hydroxyl groups and 
the base limit the possible ring conformations outside of the A form regions as well.  
Typically, most of the riboses will be in either the C2'-endo or C3'-endo conformation. 
 In the C3' endo conformation, the H3' will have a stronger NOESY cross peak 
with the intraresidue aromatic H6 or H8 proton than other intraresidue sugar protons due 
to its close proximity to the base.  This is especially evident in a NOESY experiment with 
a short mix time (<100 ms).  Another strong indicator of the sugar pucker of a base is the 
presence of a H1' to H2' cross peak in a TOCSY experiment.  If the cross peak is present, 
then the sugar must be in the C2' endo conformation.  The C3' endo conformation places 
the H1' and H2' sugar protons at a dihedral angle approaching 90º which leads to minimal 
coupling between the two hydrogens according the Karplus relationship and, thus, the 
absence of a peak in the TOCSY.  See Figure 17. 
 
Fluorescence Experiments 
2-amino purine nucleosides were used to probe the structural changes upon Isis-
11 binding.  The structure of 2-amino purine is very similar to adenine, as seen in Figure 
18, so it should not significantly disrupt RNA structure or complex formation.  The 
fluorescence of this nucleobase is sensitive to the structural environment, particularly the 
local stacking environment.  A well-stacked 2-amino purine should be somewhat 
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quenched by the neighboring aromatic n+1 and n-l bases.  An unstacked base, or a base in 




 As these studies were conducted with a racemic mixture of compound, it was 
necessary to perform structure refinement with both isomers.  Both isomers were capable 
of accommodating most of the restraints with very limited changes in the RNA structure 
or orientation of Isis-11.  Not surprisingly, the relative strengths of some intermolecular 
NOE cross peaks were more consistent with one stereoisomer than with the other.  This 
was especially true for NOEs to H11, the only proton on a chiral center.  The 
intermolecular NOE cross peak list thus represented an ensemble from both 
stereoisomers. 
Short mixing time (100 millisecond) NOE cross peaks arise from protons in close 
proximity and such interactions were given a restraint range of 1.8 to 3.0Å.  The peaks 
seen in the long mixing time data that could not be found in the short mixing time data 
were divided into two groups.  The stronger set was given a range of 1.8 to 4.5 Å while 
the weaker set was given a range of 1.8 to 5.0 or 5.5Å.  The upper bound on these weak 
restraints were sometimes restrained at 5.0 Å if we deemed the actual distance to have a 
high probability of being within 5 Å and not due to spin diffusion based on common 
RNA distances.  These restraint ranges were loosely based on the NOE cross peak 
intensities of hydrogens of known or relatively fixed distances, such as the H5-H6 cross 
peaks in the pyrimidines.  Relative intensities of intermolecular NOEs were also used to 
fine-tune some restraints in the final iterations of structure refinement.   
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Some intermolecular lower bound restraints were used in the structure calculation 
on the basis of the unambiguous absence of an NOE cross peak where one should be 
visible in the spectrum if two hydrogens were in close proximity.  Many of the 
intermolecular NOE cross peaks were very strong compared to the intramolecular RNA 
cross peaks due to the large excess of compound in the NMR samples.  Many of them 
also had very unique chemical shifts with little overlap with intramolecular RNA cross 
peaks.  Thus, it was easy to discern the absence of the peaks used as the basis for the 
intermolecular lower bound restraints.  The absence of a peak was based on the NOESY 
spectrum of the unlabeled complex and the F1fF2f spectra on the selectively labeled 
RNA complexes, as these experiments were more sensitive and thus less likely to indicate 
peak absence on the basis of inadequate sensitivity.   
Structures were calculated using a combination of Xplor-NIH 2.18 for in vacuo 
refinement by Darrell R. Davis and AMBER 10 for refinement with explicit solvation by 
Thomas E. Cheatham.  The refinement protocol for simulated annealing in torsion angle 
space described by Clore and Kuszewski for the RNA aptamer/theophylline complex and 
provided in the Xplor-NIH distribution was used with only minor changes.
80
 A notable 
exception to the distributed simulated annealing protocol was that the harmonic RDC 
potential was scaled to 0.4 to reflect the measurement uncertainty of the dipolar coupling 
measurements.  Alignment tensor calculations were done with either the calcTensor 
python script provided with Xplor-NIH, or with PALES.
81
 Electrostatic potential surface 
calculations were done using the AMBER/APBS module.
82
 Structures were visualized 
and figures prepared using PyMOL and Chimera.
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 RMS differences and average 





The specific Xplor-NIH protocol is as follows: the published free NMR 
structure
27
 was used as a model for an initial conformation of the free IRES5.  An S 
isomer of Isis-11 was docked to this using low temperature molecular dynamics with 
intra and intermolecular NOE restraints.  The starting structure was refined by restrained 
molecular dynamics in vacuo with NOE, base-pairing, and dihedral angle restraints 
(referred to hereafter as "NOE-only" restraints) to generate 20 structures.  Of the 20, 
approximately half belonged to a general consensus family with a low number of NOE 
violations and an RMSD of ~4Å.  This family of structures possessed a poor global fit 
due to a relatively low number of sequential NOEs and a lack of RDC restraints.  Several 
representatives from this family were then used independently as starting structures for 
refinement with the NOE-only plus RDC restraints.  After confirmation that each of these 
starting structures provided a similar family of 10 structures from the molecular dynamics 
refinement, one of the NOE-only refined RNA structures was used to generate a family 
of 30 complex structures for each of the Isis-11 enantiomers using NOE-only plus RDC 
restraints.  From these families of structures, 16 (R-isomer) and 19 (S-isomer) lowest 
energy model structures were refined by molecular dynamics at 300K with explicit 
solvation in AMBER applying the NOE and RDC restraints.  For each model, the > 10 ns 
length MD trajectories were clustered at 1 ps intervals into 5 groups based on the pair 
wise RMSD of all atoms of the RNA and Isis-11, and the average structure from the 
dominant cluster at the end of the simulations was minimized with implicit solvent.  
Although the entire family of structures fit the NMR data well, further energetic analysis 
from both minimization of the average structures and also MM-PBSA of the chosen 
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cluster from the MD trajectory pruned the entire set of 35 model structures to generate 





Under our standard conditions, the free RNA gave imino proton signals for the 
base pairs between G2-C37, A3-U36, G4-C35, G5-C34, C11-G33, U12-A32, G13-C31, 
U14-G30, C15-G28, U17-U26, C18-G25, C19-G24, and the tetraloop imino protons from 
G23 at and U21 at a range of temperatures between 10º and 30º C.  Upon compound 
binding, some specific imino protons resonances shift, but all base pairs remain intact 
indicating limited stem disruption. See Figure 14.  This is consistent with the placement 
of the compound in the bulge region. At very high excesses of the compound, the U14-
G30 and C15-G28 imino protons become broader, suggesting some secondary interaction 
between the compound and this region of the IRES.  
 
RNA Aromatic Protons 
The TOCSY spectrum changes are easy to follow and useful for characterizing 
Isis-11 binding.  In Figure 18, the changes of the TOCSY spectrum between the free and 
the bound RNA are shown.  Most of the H5-H6 pyrimidine cross peaks with the largest 
chemical shift changes are in and around the bulge region of IRES5.  The U9, C8, and 
C11 H5-H6 cross peaks show especially large chemical shift changes.  The C34 and C35 
H5-H6 cross peak chemical shifts also change.  The U36, C37, and C38 cross peak 
chemical shifts change to a lesser degree, and the change is directly proportional to bulge 
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proximity.  The U29 cross peak chemical shift also changes.  The line widths of U29 
remain narrow in the complex with a strong TOCSY cross peak, suggesting that U29 
remains extruded from the helix.  The cross peak chemical shifts in and very near the 
tetraloop do not appear to change at all, particularly C19-C22.  As we proceed down the 
stem and get closer to the bulge region, the cross peak chemical shifts change slightly.  
The peaks with the weakest intensities are C8 and C11.  This exchange broadening is 
consistent with binding of Isis-11 in this region.  See Figure 19. 
13
C HSQC aromatic proton spectra provide a more complete picture than the 
TOCSY because they contain peaks from both purines and pyrimidines, but these spectra 
suffer from greater spectral congestion. The overlap for the pyrimidines was particularly 
problematic.  The spectral changes were independently monitored with titrations on AU 
and GC labeled samples in addition to the fully labeled RNA in order to decongest the 
spectra.  
  The titration of Isis-11 into the free fully labeled RNA at low stoichiometric 
equivalents provides some insight into the specificity of the binding site.  G33 C8-H8, C8 
C6-H6, A6 C8-H8 are well resolved in the free 
13
C HSQC, and they are severely 
broadened at low equivalents of compound.  Other peaks that show early broadening are 
A7-H8, A10-H8, A7-H2, A32-H2, and A6-H2.  See Figure 20. 
The 
13
C HSQC on the GC labeled sample showed peak shifting mostly in and 
around the proposed binding site.  The C6-H6 cross peaks for C8 and C11 move 
significantly, as does G33.  The peaks in the tetraloop are the least affected.  G5 moved 
very little, which is somewhat counter-intuitive, but not impossible assuming that the 
degree of shielding for the residue is similar in both the free RNA and in the complex.  
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There was a surprising amount of movement for G28.  This is possibly related to the peak 
mobility seen for the U29 H6-H5 cross peak from the TOCSY.  Figure 21 shows the 
changes in the 
13
C HSQC for the GC sample upon compound binding.  
The aromatic 
13
C HSQC spectrum of the AU labeled sample showed a number of 
large changes, especially for the adenosines (H2 and H8 protons).  This is to be expected 
given the fact that all of the adenosines are relatively close to the binding site.  
Specifically, A6, A7 and A10 are all in the bulge.  A32 is very close to the bulge.  A3 is 
the most isolated from the bulge, and does not move.  The only uridine in close proximity 
to the binding site is U9, whose C6-H6 cross peak moves significantly.  The U29 C6-H6 
also changes.  In the free form, the U29 is in proximity to the bulge, so it is possible that 
compound binding alters the environment of this base sufficiently to explain this 
chemical shift change. 
There is a great deal of exchange broadening seen in the case of the adenosines. 
The A32 and A3 H2 peaks overlap based on the corresponding cross peaks in the 
NOESY spectra.  The A7 H2 peak is particularly broad and sometimes looks like two 
very slightly resolved peaks.  This might be due to slightly different binding 
environments for the two Isis-11 isomers.  It is possibly due to intermediate exchange.  
The adenosine H8 peaks are also broad in the complex.  The free and bound spectra for 
the H2 region of the 
13
C HSQC labeled RNA are shown in Figure 22.  The assigned RNA 






Nuclear Overhauser Effect Changes       
 The labeling scheme for the Isis-11 hydrogens used in the Amber structure 
refinement is summarized in Figure 23.  This same scheme will be used to describe the 
intermolecular NOE cross peaks. 
Although some geminal protons were resolved from one another (H10A-B, 
HA2A-B), it was impossible to distinguish them given the racemic mixture we were 
using.  All other geminal sets were not resolved.  Free rotation of the dimethyl groups 
resulted in redundant chemicals shifts, and thus it was not possible to distinguish methyl 
group HD1A-C from HE1A-C, and HG2A-C from HG3A-C.  In these cases, the distance 
restraints were directed to the carbon for the methylenes and to the nitrogen for the 
methyl protons of the dimethylamino groups. 
The F1fF2f and F1fF2e NOESY spectra were invaluable in distinguishing 
intermolecular NOEs from intramolecular NOEs.  A region of the unlabeled NOESY 
spectrum with overlays from F1fF2f and F1fF2e spectra is shown in Figure 24.  The 
F1fF2e experiment was particularly important for the determination of intermolecular 
NOEs between RNA protons and Isis-11 protons whose chemical shifts fell in or near the 
ranges typically occupied by RNA protons.  
In one case, this approach facilitated the assignment of some critical 
intermolecular NOE cross peaks.  There were potential NOE cross peaks from both the 
H2 from A6 and H6 from U9 to several protons on Isis-11.  Unfortunately, these two 
RNA protons had nearly identical chemical shifts in the proton dimension.  As both of 
these bases are in proximity to other bases known to interact with the molecule, either 
base could be in close proximity to Isis-11.  Fortunately, the F1fF2f data from the 
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selectively labeled complex samples cleared up this ambiguity, and it became clear the 
intermolecular NOE cross peaks were to A6-H2.  
Many of the strong intermolecular NOE cross peaks occur between Isis-11 and 
G5 and A6.  A strong NOE occurs between proton H1 of the compound and the H1' of 
G5.  There were also NOEs between G5 H1' and Isis-11 H2 and the HG3A-C and HG2A-
C methyl proton set.  There were also other strong NOEs between Isis-11 and other G5 
sugar protons.  Other pronounced and easily distinguished NOE cross peaks occur 
between H8 of this G5 and several compound protons (H11, H1, HA2A, HA2B, HG3A-
C, HG2A-C).  The large number of NOEs between Isis-11 and G5 clearly indicate that 
the binding site involves G5.  There are also a large number of NOE peaks to H2 of A6 
involving many of the same Isis-11 protons (H10A-B, H11, HG2A-C, HG3A-C, H1, H2, 
HA2A-B).  This suggests that A6 is also located in the binding site.   
There are a few weaker NOEs to G4 H1' and H8 from the HG3A-C and HG2A-C 
methyl proton set.  Some of the NOEs to this methyl set are shown in Figure 25.  Figure 
25 demonstrates the utility of the F1fF2e experiment.  The data shown clearly indicate 
that the F1fF2e experiment does an excellent job of filtering out intramolecular NOEs 
from Isis-11, which are typically very strong given the excess of Isis-11 relative to 
IRES5.  The Isis-11 H1 to HG3A-C and HG2A-C methyl proton set peak is screened out 
completely in the F1fF2e experiment.  Another fortunate outcome of this experiment is 
that it enabled us to see the intermolecular G5-H8 to HG3A-C and HG2A-C methyl 
proton set cross peak that would otherwise be mistaken for the intramolecular Isis-11 H2 
to HG3A-C and HG2A-C methyl proton set cross peak.  The common chemical shift of  
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G5-H8 and Isis-11 H2 would otherwise have made any intermolecular NOE assignments 
involving G5-H8 very doubtful.       
 There are few NOE cross peaks to the hydrogens of the dimethylamino group on 
the long methylene arm (protons HD1A-C and HE1A-C) and the methylene arm itself.  
There is, however, one strong and unambiguous NOE cross peak between the H5 on U12 
and the methyl protons.  There is also an NOE cross peak from H5 of C11 to these 
methyl protons (HD1A-C, and HE1A-C).  This anchors that end of the molecule in the 
structure and proved to be critical for convergence in the structure refinement.  See 
Figure 26. 
In contrast to the paucity of NOEs for the long arm, there were a number of strong 
NOE cross peaks to the protons of the dimethylamino group of the short methylene arm 
(protons HG3A-C and HG2A-C).  The cross peaks to these protons were easily 
distinguished due to their chemical shifts being upfield of the ribose sugar region.  This 
was true for all the methyl protons and most of the methylenes in Isis-11.   
There were also a number of NOE cross peaks to the H11 proton, which sits on 
the lone chiral center of Isis-11.  Of course, as this is a racemic mixture of Isis-11, it must 
be taken into account that the NOE cross peaks to Isis-11 could be based on the binding 
of either the R or S isomer.   




The ribose sugar conformations for the complex were predominantly 3' endo, as 
expected.  The few sugar pucker conformations that could not be determined 
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unambiguously were left unrestrained in the structure calculations, as were the 2' endo 
sugars.  The sugar conformations in the complex are summarized in Table 5.   
 
Residual Dipolar Couplings  
The measurements of the C6-H6 and C5-H5 from the pyrimidines and the C8-H8, 
and C2-H2 from the purines were of generally good quality. The fitting of the RDC 
measurements in the calculation of the structure yielded good alignment with very few  
violations.  The list of RDC constraints used in the structure calculation is shown in Table 
6.  Figure 27 shows a portion of the aligned IPAP 
13
C HSQC data from the G and C 
labeled sample.  
 




H chemical shifts of Isis-11 were dominated by the unbound form due to the 
high excess of compound relative to the RNA.  Most of the protons in the complex were 
in fast to intermediate exchange; nevertheless, the aromatic (H1 and H2) and chiral (H11) 
compound protons were in slow exchange as a result of significant chemical shift 
changes between the bound and free forms.  These assignments and this exchange 
behavior were confirmed with ROESY NMR experiments in which the phase of the cross 
peak between the free and bound forms of the same proton was the opposite of the phase 
of the other NOE cross peaks.  The significant upfield shift is consistent with the 
placement of these protons near the center of the pi electron cloud of an aromatic group.  
While this information was too vague to admit as a specific restraint in the structure 
refinement, it did inform our analysis of the results.  Given that these protons sit in a 
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rigid, relatively flat, mostly aromatic portion of Isis-11, this might mean that these 




Melting experiments done by the Hermann group have demonstrated that the 
presence of divalent metals not only raises the Tm of domain IIa, but also increases the 
cooperativity of melting. 
26
 As this molecule is known to bind near the critical Mg
2+
 
binding site of the RNA, we were curious as to how the molecule would affect the Tm in 
the presence and absence of Mg
2+
.   
 At a pH of 7 (10 mM sodium phosphate), in the absence of Mg
2+
 and in the 
presence of 50 mM NaCl and KCl, the IRES5 construct showed a small drop in the Tm in 
the presence of an excess of Isis-11.  The free RNA yielded a Tm of 62.5±0.5°C while the 
complex yielded a Tm of 61.6±0.2°C.  This is consistent with the model in that it indicates 
that there is not significant secondary structure disruption in the presence of the 
compound.  While Isis-11 may bind near Mg
2+
 binding sites on the RNA, it does not have 
the same stabilizing effect since the Tm does not go up. 
 Given the apparent importance of Mg
2+
 in the complex, melting was studied in the 
presence of 1 mM MgCl2.  The salt concentration was lowered to 10 mM KCl and NaCl 
in order to lower the Tm and thus avoid the Mg
2+
 facilitated RNA hydrolysis at high 
temperatures.  It was also necessary to keep the monovalent salt concentration low in 
order to avoid raising the Tm above the point at which it could be accurately measured in 
water.  The sample was buffered at pH 7 with 10 mM sodium phosphate.  In the absence 
of compound, the Tm was 68.3±0.4°C.  In the presence of an excess of Isis-11 the Tm was 
slightly reduced (67.5±0.8°C).  It is interesting that the compound lowers the Tm by about 
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-free samples.        
 For the sake of comparison, the Mg
2+
 free melting study on IRES5 in the absence 
of compound was conducted a second time with lower salt concentrations as in the Mg
2+
 
experiment described above.  At 10 mM KCl and NaCl and 10 mM sodium phosphate pH 
7, the Tm was determined to be 55.1±0.5°C.  This is significantly lower than the Tm of the 
free IRES5 with Mg
2+ 
(68.3±0.4°C).  This is consistent with the general phenomenon of 




 In summary, the compound does not appear to significantly facilitate melting of 
the RNA, although it does consistently drop the Tm by approximately 1° C in the 
presence and absence of Mg
2+
.  It also does not appear to stabilize the helix significantly.  
This is consistent with the placement of the compound in the bulge with limited 
perturbation of the upper and lower stems.   
 
Fluorescence 
The fluorescence of 2-aminopurine substituted RNAs at positions A6 and A7 
increases upon compound binding.  This is consistent with the unstacking of these bases.  
The fluorescence of the A10 2-aminopurine substituted RNA is more quenched upon 
compound addition, suggesting a higher degree of stacking in the complex.  
The fluorescence intensity at 370 nm for the A6 2-aminopurine was also 
measured as a function of compound concentration in order to estimate the KD.  The 
fluorescence change upon compound binding was consistent with a simple two-state 
binding model.  This curve fit indicated a KD of approximately 2.4 µM, which is 
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consistent with the value reported previously.
54
 The change in fluorescence for the A6 2-
aminopurine titration can be seen in Figure 28.  
 
Structures and Statistics 
 
The structure was refined for both the S and R isomers.  Given the limited number 
of both intra- and intermolecular NOE restraints, the convergence is good. The RMSDs 
of the R and S isomers were 1.7 and 2.2A, respectively.  The R-isomer structures tend to 
have fewer bond and torsion violations, lower free energies for the RNA plus Isis-11 
complex, and more favorable RNA free energies.  Greater convergence to a common 
structure was also seen with the R isomers.  The free energy of the binding of Isis-11, 
however, is comparable between the two isomers.  See Table 7. 
The convergence is worst in the area with the fewest restraints, namely the A7-C8 
region of the bulge.  There is also a high degree of mobility for U29, which is probably 
flipped out most of the time, but appears to sample a number of conformations.  The 
convergence of the Isis-11 placement in the bulge is remarkable, as is the high degree of 
similarity between the R and S stereoisomer structures.  The superpositions of the 10 
lowest energy structures for the two structures are shown in Figure 29. 
The fluorescence changes described previously are consistent with the structural 
changes indicated in NMR experiments.  The NMR structure suggests that U9 flips in 
and becomes stacked with the A10.  The structure also shows A6 unstacks from G5 and 
A7 and interacts with the molecule.  A7 is unstacked from A6.  It is not entirely clear 
what C8 is doing, but there are some NOE cross peaks to A7 that are consistent with, if 





Interestingly, both isomers could be reasonably well accommodated in very 
similar RNA structures with limited violations.  At first glance, the structures appear 
identical.  Both isomers occupy essentially identical binding sites.  Both are in largely 
extended conformations.  This is consistent with the absence of NOEs between the 
dimethylamino side chains. 
Given the additional fact that the two aromatic protons (H1 and H2) and the chiral 
proton (H11) of Isis-11 are significantly shifted upfield, the two families of structures 
must also be judged on the basis of the placement of these protons near the face of an 
aromatic group.  In the S Isomer, the tricyclic body of Isis-11 is largely stacked between 
G5 and A6 with the two aromatic protons in fairly close proximity to the aromatic face of 
G5.  The H11 proton is positioned under the face of A6.   See Figure 30.  
In the R isomer, the body is also similarly stacked, and the two aromatic protons 
are also consistently placed near the face of G5, though not as directly as was the case 
with the S isomer.  The placement of H11 is less ideally situated over an aromatic face, as 
it is facing away from A6 and is not situated over G5.  The Amber refinement suggests 
that the two isomers bind with similar affinity.  The visual similarity of the refined 
structures is consistent with this conclusion.  See Figure 31.   
While all titrations and NMR experiments were conducted with a racemic mixture 
of Isis-11, this mixture was later separated via chiral HPLC.  While the individual 
isomers could not independently be characterized as S or R, independent fluorescence 
titrations were performed to measure the KDs.  The two isomers were found to bind with 
very similar affinities (9.0 M and 2.8 M) in low salt conditions. 
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Comparison to Published Structure 
The Puglisi structure indicates a significant bend in domain IIa.27 This has been 
corroborated by crystallographic studies performed by the Hermann group.26 Domain IIa 
is known to contain several specific magnesium binding sites, and the magnesium is 
known to stabilize the single stranded region involved in the domain IIa bulge.  Residues 
6, 7 and 8 of this single-stranded region are stacked on the G5-C34 base pair, resulting in 
a continuous helical arrangement of these three bases over the lower stem.  The 
accommodation of this motif produces an 84.5 ± 9.6˚ bend. Our construct, in the absence 
of the Isis-11 compound, was found to adopt essentially the same bent structure both in 
the presence and absence of magnesium, based on RDC measurements.  Our structure 
suggests that compound binding induces significant straightening of this domain IIa 
bulge.  Several independently acquired RDC sets were only consistent with this straight 
structure.  See Figure 32.   
 Compound binding impacts the stacking and arrangement of the bases in the 
bulge.  The free RNA shows continuous stacking from the 5' terminus (G1 in our 
construct) through C8 with U9 largely flipped out.  Compound binding appears to swing 
out the A7 through A10 portion of the bulge from its previous position stacked over A6 
through the terminus in such a way that A7 is very distant from G5.  Concomitantly, the 
previously flipped out U9 becomes stacked with A10 on the C11-G33 base pair.  See 
Figure 33.  The NMR RDC fits indicate that the helical regions on either side of the bulge 





It is beyond the scope of this study to definitively suggest a mechanism of 
inhibition for Isis-11 on HCV domain II; however, it is tantalizing to suggest a possible 
mechanism based on what is known about domain II and its involvement in IRES 
mediated translation.  The straightening of the structure upon compound binding is 
possibly the mode of action for the inhibition of IRES function.  Cryo-EM studies by 
Siridechadilok et al indicate some proximity between domain IIa and elements of eIF3, 
but mutational studies have indicated that this domain has a negligible impact on eIF3 
recruitment.
23
 The only portion of domain II that is known to have a specific role in IRES 
function is the apical loop of domain IIb.  While the compound does not directly interact 
with the apical loop portion of domain II, the conformational change in the RNA would 
move the domain terminus.  As the lower portion of domain II is constrained by its 
attachment to the tightly bound domain III, it is immobilized in the translation initiation 
complex.  The straightening of domain II should displace the apical loop from its position 
over the mRNA cleft at the ribosomal E site.  This displacement could keep the apical 
loop from interacting with the ribosome and facilitating GTP hydrolysis and eIF2 release 
prior to 60S recruitment.  See Figure 34.  In this sense, Isis-11 could be considered an 
allosteric drug if we think of the domain IIb terminus as the "active site" of domain II.  
By binding in domain IIa, which is distal to the "active site", a conformational change is 
induced in the "active site" that prevents the "active site" from performing its catalytic 




The only alternative mechanism of action that I can conceive is that the com-
pound impedes the binding of initiation factors or binding to the 40S subunit. However, 
this seems unlikely given that domain II has been shown to be unnecessary for 40S 
binding, and it is not known to bind to any initiation factors. 
Multiple sets of RDC restraints were shown to be only consistent with the straight 
structure.  Recently published results from the Hermann lab have also suggested a 
conformational change in domain IIa upon inhibitor binding.
86
 These FRET assays were 
performed with a similar tight binding benzimidazole compound first described by Isis 
Pharmaceuticals (compound 13 in the published account, Isis-13 hereafter)
54
.  The 
conformational widening of the inter-helical angle by 23º C indicated by their data 
corroborates our general findings.  The Hermann group also performed titrations of Isis-
13 into an A7 2-aminopurine substituted IRES construct sample.  In agreement with our 
findings with Isis-11 and a similar 2-aminopurine substituted IRES construct, they found 
that fluorescence, and thus destacking at the A7 position, increased upon Isis-13 
addition.
86
   
 The binding of Isis-11 appears to be driven by stacking interactions as well as by 
cation-pi interactions.  The tricyclic, largely aromatic body of Isis-11 is stacked between 
A6 and G5.  The primary amine may be involved in a cation-pi interaction with G33.  
The tertiary amine on the short methylene arm may also be involved in a cation-pi 
interaction with A6.  Although the architecture in and around the binding site has 
changed significantly from the free RNA, the placement of these amines in the complex 
may loosely approximate the placement of specific Mg
2+
 ions seen in the free structure.
26
 
See Figure 35. 
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It is interesting to note that electrostatic considerations are an important part of 
the binding interaction, but not in the obvious way we might have anticipated.  The 
negative charge on the phosphate backbone is largely canceled out by the high 
concentration of monovalent counter cations.  This leads to the predominance of more 
subtle negative charges elsewhere on the RNA that can interact with the positively 
charged amines on Isis-11.  Figure 36 shows the electrostatic potential surface calculated 
for the RNA alone using the structure of the complex.  As shown in the figure, the two 
tertiary amine groups of Isis-11 nestle into a region of predominantly negative potential, 
even though they are not interacting with the phosphate backbone. 
It has been suggested that by Begley and Varani in describing the results of 
Parsons et al. that small molecules, such as the one in this study, "that binds the hepatitis 
C viral genome by 'locking' in a particular RNA conformation to inhibit viral protein 
production suggests a new paradigm for drug design."
87
 They point out several 
advantages to the approach of directly targeting viral RNA, specifically the HCV IRES, 
but analogies could be made to other viral RNA systems.  Firstly, the 5'-UTR of HCV 
contains some of the most highly conserved genome sequences of an otherwise highly 
mutation prone viral family.  Secondly, the unique conformational flexibility of RNA, so 
crucial to its interactions with various cellular targets, becomes the point of attack.  The 
abolition of this flexibility represents a heretofore-unexploited arena for viral inhibition.  
Thirdly, by targeting the RNA itself rather than attempting to disrupt the interaction 
between the RNA and a protein, the small molecule does not have to compete 
energetically or sterically with the protein.  
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In summary, this structure suggests the possibility of a novel mode of inhibition 
of hepatitis C virus.  More broadly, this structure suggests the possibility of a new 
approach to drug design.  This structure may also provide the basis for the future 
improvement of the binding affinity of this inhibitor class as later compounds are 
designed to better fit the binding site and take better advantage of potential energetically 
favorable binding interactions.

































Figure 18: 2-aminopurine and adenine structures.  2-aminopurine nucleosides were used 
in lieu of selected adenosines in order to probe changes in the stacking of the IRES5 





Figure 17: Common sugar puckers in RNA.  (A) Planar sugar ring, never observed.  (B) C3'-
endo sugar pucker.  This conformation is the norm in A form helical RNA.  (C) C2'-endo 
sugar pucker.  This conformation is the norm in B form helical DNA.  This conformation is 








Figure 19: TOCSY spectrum of free and bound IRES5.  The cross peaks with negligible movement are labeled in violet.  The 
free spectrum is shown and labeled in blue while the bound spectrum is shown and labeled in red.  Some of the peaks that 
show the most movement are highlighted with black arrows.  Adapted from Paulsen et al (2010).  
  
 
 Figure 20: Specific line broadening in the complex.  Low equivalents of Isis-11 lead to specific line broadening.  A) Portion 
of the 13C HSQC spectrum in the absence of Isis-11.  B) Portion of the 13C HSQC spectrum in the presence of ~0.5 





Figure 21: 13C HSQC spectrum of free and bound GC labeled IRES5.  The free RNA spectrum is shown in blue and the bound 
RNA spectrum is shown in red.  Peaks that overlap in the free and bound forms are labeled in violet.  The asterisk indicates an 





Figure 22: The H2 region of the 13C HSQC spectrum of free and bound IRES5.  The free 
RNA spectrum is shown and labeled in blue and the bound RNA spectrum is shown and 
labeled in red.  






Figure 24: Application of filter/edit suite of experiments to IRES5.  The different data sets provide a clear distinction between 

















Figure 25: NOEs to the HG3A-C and HG2A-C methyl proton set.  A) Selected region of the NOESY spectrum of the unlabeled 
IRES5-Isis-11 complex.  B) Selected region of the F1fF2e NOESY spectrum of the fully labeled IRES5-Isis-11 complex.  The 
F1 'filter' purge of the F1fF2e experiment yields NOEs only where the ω 1 frequency corresponds to the unlabeled Isis-11 proton.  
One intermolecular NOE (to G5-H8) and one intramolecular NOE (to Isis-H2) overlap.  The F1fF2e experiment is less sensitive 
than the conventional NOESY, and weaker intermolecular NOEs do not appear in the F1fF2e spectrum.  Adapted from Paulsen 







Figure 26: Intermolecular NOEs from the HD1A-C and HE1A-C methyl set and the HG3A-C and HG2A-C methyl set to 
IRES5.  The data shown are from a NOESY spectrum on an unlabeled complex.  The resolution of these two Isis-11 methyl 
proton sets can clearly be seen in this figure.  Adapted from Paulsen et al (2010). 
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 Figure 27: Residual dipolar couplings of the bound IRES5.  Residual dipolar coupling 
measurements for a selection of guanosine C8-H8 bond vectors in the aligned complex 
sample.  The unaligned 1JCH value for the C8-H8 vector in guanosine is 214.9 Hz. 
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Figure 28: Fluorescence spectroscopy of IRES RNA with 2-aminopurine at position A6.  The RNA concentration is 1 µM 
in 10 mM sodium cacodylate, pH 7.0 and 50 mM NaCl.  Isis-11 was titrated at 0.6, 12, 24, 36, 66, 126, 186, 246, 546, 
846, 1146, 1746, 2346, 2946, 2546, 4146 and 4746 nM.  Fluorescence response increased with inhibitor concentration, 
consistent with decreased stacking upon compound binding.  The fluorescence intensity at 370 nm was fit to a simple two-
state binding model to yield a KD of 2.4 µM.  Adapted from Paulsen et al (2010). 
  
 
 Figure 29: Superpositions of IRES5-Isis-ll complex structures. A) Superposition of 10 lowest energy structures of the R isomer 























Figure 30: A6 - Isis-11 interactions consistent with upfield shift.  Molecular graphics 
highlight the favorable orientation of A6 to the chiral proton of the S-isomer.  This 
orientation is consistent with the upfield shift upon compound binding.  The averaging of 
the NOEs due to both isomers being present appears to promote structures where A6 
stacks over the benzimidazole rather than structures where A6 is involved in a cation-pi 
interaction with the dimethylamino group that would shield the H11 proton.  Adapted 
from Paulsen et al (2010). 
Figure 31: R and S isomer binding modes.  Molecular graphics (local fit) of the S-isomer 
and R-isomer for Isis-11 after MD refinement in explicit solvent with the 
ff99SB+parmbsc0 force field.  Shown are the lowest energy structures from a local fit 
over residues 5, 10, 11, 33, and 34 for each isomer (colored yellow and green).  Adapted 
from Paulsen et al (2010).  
  
 Figure 32:  NMR structures and residual dipolar coupling data. (A) RDC fit. CH RDCs were calculated from a representative 
final complex structure and from the free RNA starting structure; each set of calculated RDCs is plotted against the 
experimental RDC set for the complex.  Filled squares are for the complex, and open circles for the free RNA. (B) The free 
RNA model (black) is shown superimposed (residues 12:19,24:32) on the complex structure (orange backbone) illustrating 












Figure 33: Bulge base stacking adjustments in complex. (A) Molecular graphics of the heavy atoms of the free first three 
models from PDB 1P5M and (B) Isis-11 bound RNA structures (the two lowest energy water-refined structures from each 
stereoisomer).  The residues whose environment changes upon binding are labeled and colored (C11, C34, C35: red; C8, U9: 
yellow; G5, A6, A7: magenta; A10: cyan; G33:green; Isis-11: gray).  The structures were fit using residues 5-11, 33-34 for 








Figure 34: Proposed mechanism of inhibition.  (A) Domain IIa of the HCV IRES has a 90° bend that positions the apical loop 
of domain II in contact with the 40S subunit near the E-site, and along with eIF5, promotes hydrolysis of eIF2-GTP and 
subsequent release of eIF2-GDP.  (B) The release of eIF2-GDP allows recruitment of the 60S subunit and eIF3 release (not 
shown) to assemble a translation competent 80S ribosome.  (C) The inhibitor (X) would straighten IRES domain II, reduce the 
eIF2-GTP hydrolysis rate, and slow 80S assembly.  Adapted from Paulsen et al (2010). 
 
 






Figure 35: Stereo image of potential cation-pi interactions between IRES5 and Isis-11.  Possible cation-pi interactions are 




 Figure 36: Electrostatic surface potential of the complex. The electrostatic potential surface was calculated for the RNA only 
using the structure of the complex.  Areas of highest negative charge are colored red and are localized near the dimethylamino 





          
Complexed RNA 1H chemical shifts (ppm) 
                    
Residue H8/H6 H5/H2 H1' H2' H3' H4' H5' H5" imino 
G1 8.15 - 5.75 4.89 4.68 4.57 n.d. 4.30 n.d. 
G2 7.50 - 5.89 4.64 4.90 n.d. n.d. n.d. 12.25 
A3 7.81 7.51 6.01 4.70 4.69 n.d. n.d. n.d. - 
G4 6.96 - 5.58 4.47 4.31 n.d. 4.41 4.05 12.64 
G5 7.16 - 5.77 4.15 4.47 n.d. n.d. n.d. 12.12 
A6 7.75 7.92 5.94 4.11 4.31 n.d. n.d. n.d. - 
A7 8.43 8.12 6.08 4.86 4.91 n.d. n.d. n.d. - 
C8 7.87 6.02 5.75 4.05 4.84 n.d. n.d. n.d. - 
U9 7.92 5.99 6.01 4.51 4.80 n.d. n.d. n.d. n.d. 
A10 8.57 8.18 6.14 4.86 4.77 n.d. n.d. n.d. - 
C11 7.45 5.75 5.09 4.33 4.86 n.d. n.d. n.d. - 
U12 8.04 5.55 5.79 4.95 4.55 n.d. n.d. n.d. 13.84 
G13 7.78 - 5.89 4.76 n.d n.d. n.d. n.d. 12.53 
U14 7.85 5.41 5.51 4.29 4.47 n.d. n.d. n.d. 12.09 
C15 7.93 5.61 5.54 4.39 4.44 n.d. n.d. n.d. - 
U16 7.92 5.49 5.52 4.01 n.d n.d. n.d. n.d. n.d. 
U17 7.77 5.36 5.49 4.29 4.51 n.d. n.d. n.d. 10.62 
C18 8.08 5.97 5.72 4.52 n.d n.d. n.d. n.d. - 
c19 7.62 5.64 5.57 4.62 4.19 n.d. n.d. n.d. - 
u20 7.87 5.73 5.66 3.84 4.57 n.d. n.d. n.d. 11.77 
u21 8.07 5.91 6.11 4.69 4.08 n.d. 4.28 n.d. n.d. 
c22 7.73 6.19 5.98 4.15 4.55 n.d. n.d. n.d. - 
g23 7.90 - 6.00 4.92 5.62 n.d. n.d. n.d. 9.73 
g24 8.28 - 4.61 n.d. 4.35 n.d. n.d. n.d. 12.81 
G25 7.20 - 5.81 4.71 4.32 n.d. n.d. 4.05 13.30 
U26 7.66 5.34 5.44 4.13 4.42 n.d. n.d. n.d. 11.36 
C27 7.81 5.45 5.52 3.79 4.59 n.d. n.d. n.d. - 
G28 7.73 - 5.85 4.67 4.81 n.d. n.d. n.d. 12.46 
U29 7.76 5.79 5.92 4.42 4.68 n.d. n.d. n.d. n.d. 
G30 7.57 - 5.72 4.52 4.57 n.d. n.d. n.d. 11.39 
C31 7.85 5.41 5.56 4.52 n.d n.d. n.d. n.d. - 
A32 8.02 7.50 6.08 4.87 4.76 n.d. n.d. n.d. - 
G33 7.23 - 5.85 4.46 4.82 n.d. n.d. n.d. 13.44 
C34 7.76 5.80 6.10 4.49 4.75 n.d. n.d. n.d. - 
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Table 2 continued 
                    
Residue H8/H6 H5/H2 H1' H2' H3' H4' H5' H5" imino 
C35 7.76 5.87 5.61 4.17 n.d. n.d. n.d. n.d. - 
U36 7.90 5.30 5.50 4.47 n.d. n.d. n.d. n.d. 13.84 
C37 7.93 5.64 5.59 4.22 n.d. n.d. n.d. n.d. - 
C38 7.70 5.49 5.74 4.05 4.21 n.d. n.d. n.d. - 
Imino 1H assignments determined at 10° C.  Non-exchangeable 1H  
assignments determined at 35° C.  All assignments determined in 10 mM 
sodium phosphate buffer, pH 7.0, 150 mM NaCl, 150 mM KCl, 2mM 






































    Complexed RNA 1H chemical shifts (ppm) 
 
   Residue C8/C6 C5/C2 N1/N3 
G1 138.9 - n.d 
G2 136.6 - 143 
A3 139.2 153.6 n.d 
G4 135.2 - 143.4 
G5 135.5 - 144 
A6 139.2 154.4 n.d 
A7 141.8 155.5 n.d 
C8 143.7 99.3 n.d 
U9 143.9 105.9 n.d 
A10 141.7 154.7 n.d 
C11 141.7 98.5 n.d 
U12 142.4 103.5 n.d 
G13 136.5 - 143.5 
U14 140.8 103.8 n.d 
C15 141.9 97.6 n.d 
U16 141.6 102.9 n.d 
U17 142.4 102.8 153.8 
C18 142.2 98.1 n.d 
c19 141.3 98.5 n.d 
u20 141.1 104.9 n.d 
u21 144.7 105.4 n.d 
c22 142.9 98.7 n.d 
g23 142.9 - n.d 
g24 138.7 - 143.7 
G25 135.8 - 144.8 
U26 140.6 103.7 155.1 
C27 142.1 96.5 n.d 
G28 137.3 - n.d 
U29 144.1 105.0 n.d 
G30 137.6 - n.d 
C31 142.0 96.8 n.d 
A32 138.5 153.6 n.d 
G33 135.2 - n.d 
C34 141.9 98.6 n.d 
C35 141.8 98.5 n.d 
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    Table 3 continued 
    Residue C8/C6 C5/C2 N1/N3 
U36 142.4 102.8 158.8 
C37 142.0 97.2 n.d 
C38 141.9 98.0 n.d 
15N assignments determined at 10° C.  13C 
assignments determined at 35° C.  All assignments 
determined in 10 mM sodium phosphate buffer, pH 
7.0, 150 mM NaCl, 150 mM KCl, 2mM spermine.  
Residues added for construct stability are shown in 
lowercase letters. 
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IRES5 proton Isis-11 proton or proton group 
G4 H1' HG3A-C, HG2A-C 
G4 H8 HG3A-C, HG2A-C 
G5 H1' H1 
G5 H1' H2 
G5 H1' HG3A-C, HG2A-C 
G5 H2' H1 
G5 H3' H11 
G5 H8 HA2A-B 
G5 H8 H11 
G5 H8 HG3A-C, HG2A-C 
G5 H8 H1 
A6 H1' HG3A-C, HG2A-C 
A6 H2 H11 
A6 H2 H10A 
A6 H2 H10B 
A6 H2 HA2A-B 
A6 H2 HG3A-C, HG2A-C 
A6 H2 H1 
A6 H2 H2 
A6 H8 HG3A-C, HG2A-C 
A7 H8 HG3A-C, HG2A-C 
C11 H5 HD1A-C, HE1A-C 






















Summary of ribose sugar puckers in the complex 
 
3' endo  2' endo Unknown 
G1, G2, A3, G5, 
A7, A10, C11, 
U12, G13, U14, 
C15, U16, U17, 
C18, C19, U20, 
G23, G25, U26, 
C27, G28, G30, 
C31, A32, U36, 
C37, C38 
G4, A6, U9, 
U21, C22, U29, 
G33,  






       
13C and 15N RDCs 
       
Residue Bond vector RDC (Hz)  Residue Bond vector RDC (Hz) 
A3 C2-H2 22.05  G5 C8-H8 21.8 
A6 C2-H2 20.1  C11 C6-H6 9.4 
A7 C2-H2 4  G13 C8-H8 12.84 
A10 C2-H2 18.19  C18 C6-H6 18.51 
A7 C8-H8 8.4  C18 C5-H5 32.88 
U9 C6-H6 11.17  C19 C5-H5 15.78 
A10 C8-H8 22.45  C19 C6-H6 12.56 
U12 C6-H6 17.21  C22 C6-H6 12.24 
U16 C6-H6 30.16  C22 C5-H5 -25.9 
U17 C6-H6 25.93  G23 C8-H8 19.9 
U21 C6-H6 19.7  G23 C1'-H1' 21.4 
U29 C6-H6 4.1  G24 C8-H8 9.7 
A32 C8-H8 8.4  G25 C8-H8 15 
U36 C6-H6 12.32  C27 C5-H5 21.52 
U21 C5-H5 6.99  G28 C8-H8 32.1 
U26 C5-H5 6.92  G30 C8-H8 26.8 
U29 C5-H5 0.92  G30 C1'-H1' -6.9 
U36 C5-H5 13.92  C31 C5-H5 20.28 
A3 C1'-H1' -6.92  G33 C8-H8 11.1 
A6 C1'-H1' 12.62  C37 C5-H5 22.78 
A7 C1'-H1' -2.92  C38 C5-H5 15.3 
U9 C1'-H1' -2.22  G2 N1-H1 12.67 
A10 C1'-H1' -8.52  G4 N1-H1 16 
U20 C1'-H1' 20.62  G5 N1-H1 24.75 
U21 C1'-H1' 18.67  G13 N1-H1 14.4 
G1 C8-H8 22.6  U17 N3-H3 22.4 
G1 C1'-H1' -11.6  G24 N1-H1 16.1 
G2 C8-H8 21.6  G25 N1-H1 22.4 
G4 C8-H8 10.9  U26 N3-H3 31.28 
G4 C1'-H1' -3.6   U36 N3-H3 9.8 







   
NMR restraints and structural statistics  
   
Experimental Restraints     
 RNA intra-molecular NOE distance restraints 295  
 Inter-molecular NOE upper bounds 23  
 Inter-molecular NOE lower bounds 21  
 Hydrogen bond distance and planarity restraints 40  
 Dihedral restraints (chi, delta, gamma) 94  
 RDC restraints 60  
Structure statistics
1
 S-isomer R-isomer 
Violations   
    Distance violations –mean #, (s.d.) 108.1 (6.33) 102.9 (2.32) 
    Distance violation size - mean distance in Å, (s.d.) 0.028 (0.099) 0.021 (0.064) 
    Dihedral angle constraints - mean #, (s.d. in °) 1.75 (9.00) 2.26 (12.24) 
    RDC– mean value in Hz, (s.d) 1.33 (1.16) 1.05 (0.90) 
Deviations from idealized geometry   
    Bond lengths (Å) – mean value 0.01 0.01 
    Bond angles (º) – mean value 2.54 (0.03) 2.52 (0.03) 
RMS difference for structures
2
 (Å)   
    All RNA atoms + Inhibitor  2.3 (1.5) 1.7 (1.1) 
1
Mean and standard deviations (SD) violations/deviations from experimental restraints 
over 10 structures for each isomer. 
2
RMS difference calculated between structures, and rms difference from the mean 




















T7 PRODUCTION OF LONG RNAS WITH HOMOGENEOUS ENDS 
 
 The standard methodology for the production of long RNAs with homogenous 3' 
ends has been the use of ribozymes at the 3' end.  These self-cleaving ribozymes leave 
clean, homogenous 3' ends, which can subsequently be used for ligation reactions 
requiring such clean ends.  The problem with this methodology, at least in our 
experience, was that the yields were poor.  The low yield could be ascribed to a number 
of possible reasons.  For one, the addition of the ribozyme necessitated the use of long 
(>100 bases) DNA templates.  These templates were too long, in most cases, to be 
synthesized in high yields by the synthesis core at the University of Utah.  Thus, the 
DNA templates were incorporated into plasmids.  Plasmid purification and subsequent 
endonuclease cleavage and purification did not lead to very clean product compared to 
the synthetic product provided by Dr. Schackmann and coworkers at the DNA synthesis 
core facility.  It is possible that the DNA impurity created an additional variable that 
made T7 reaction optimization and subsequent ribozyme self-cleavage reactions more 
challenging than was anticipated.  Ribozyme cleavage yields were poor, further limiting 
yield, and complicating RNA preparation.    
Good yields were obtained with a T7 system that utilized a single stranded DNA 
template and a complementary 17 base single strand "top" oligonucleotide, forming a 
double stranded recognition sequence for the T7 enzyme at the 3' end of the DNA 
  
template.  The problem of 3' heterogeneity in the RNA could be assuaged by the use of 2' 
O-methyl substituted nucleotides at the 5' end of the template strand.  These bulky O-Me 
groups tend to force the sugar into the 3' endo sugar conformation, which promotes A 
form helix formation and stability.  This promotes stability at the 5' terminus of the single 
stranded template between the DNA and the 3' end of the nascent RNA, which leads to 
homogeneous 3' ends of the RNA product.  A limitation of this method is the maximum 
length of the DNA template is restricted by the efficiency of chemical DNA synthesis; as 
the DNA must be chemically synthesized to incorporate the 2' O-Me groups, it is subject 
to the usual yield limitations mentioned above. 
A new method was developed to incorporate the ribozyme-obviating 2' O-Me 
groups into the plasmid-based approach for making long RNA oligonucleotides.  PCR 
could be performed on the plasmid of interest employing primers incorporating the 2' O-
Me.  We found that these altered primers worked as well as conventional primers in the 
colony PCR reaction.  In this way, we were able to produce high yields of double 
stranded DNA ready for T7 synthesis.  It was found that this template produced very 
clean, homogeneous ends as determined by mass spectrometric analysis.  
While it seems as though someone else should have thought of this already, I am 
unaware of any published record describing this methodology.  While we were unable to 
follow up on this to a sufficient degree to attempt to publish it independently, it proved 
very successful in producing long homogenous RNAs in good yields for other projects 









PRODUCTION OF ISOTOPICALLY LABELED RNTPS  
FROM LABELED MINIMAL MEDIA 
 
  
With the availability of inexpensive commercially available isotopically labeled 
rNTPs, it has become less necessary to produce these rNTPs for production of 





N labeled ammonium chloride in reasonable yields and at reasonable cost.  




E. coli is grown in minimal media and the ribosomes are harvested, fully 
hydrolyzed and phosphorylated to rNTPs.  Given that the ribosome is found in similar 
amounts in all E. coli strains, any hardy strain is probably acceptable.  This cell culture 
may be simultaneously used to produce isotopically labeled protein or tRNA.  
Isotopically labeled glucose is added at five grams per liter and isotopically labeled 
ammonium chloride is added at one gram per liter.  Typically, M9 minimal media 
supplemented with trace metals was used, although other minimal media should work as 
well. 
Cells in the trace metal minimal media can grow to A600 of four.  The cells are 
resuspended in Pardi buffer C and then lysed with lysozyme and the use of a French 
press.  The lysate is then centrifuged at 5000 rpm to remove the cell debris.  The 
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supernatant is centrifuged overnight at 100,000 G, thus forming a pellet of the ribosomal 
RNA.  This supernatant will contain most of the soluble protein and tRNA and may be 
harvested independently for the macromolecules of interest.  The ribosomal pellet is then 
resuspended in STE buffer (approximately 10 grams of cells in 40 mLs of buffer) and 
phenol/chloroform extracted to remove the ribosomal protein material.  The rRNA is then 
quantified by A260 measurement.  Nuclease P1 provided by Sigma or other sources is then 
uses to hydrolyze the rRNA to rNMPs.  This reaction is monitored by HPLC on an ion 
exchange column. 
The rNMPs can be converted to rNTPs through an enzymatic reaction involving 
pyruvate kinase, nucleoside monophosphate kinase, myokinase or adenylate kinase, and 
guanylate kinase as described by Niconowicz et al.
88
 This reaction is monitored by HPLC 
employing a Vydac ion exchange column.  The initial buffer (A) consists of 0.045 M 
sodium formate (pH 4.5).  The secondary buffer (B) consists of 0.5 M NaH2PO4 (pH 2.5) 
This method calls for a gradient of 0 to 100 % B over 10 minutes continuing with B 
buffer for 10 minutes. This method can readily resolve all four rNTPs from one another 
and from rNMPs.  The reaction can reach 90% completion, but 80% is typical.  The 
reaction mixture may be injected directly onto the HPLC column.  The rNDPs are 
produced transiently in the reaction process, but are never present in large enough 
concentrations to see in the chromatograms.   
The rNTPs have to be cleaned up prior to use in a T7 reaction.  This is done with 
a boronate affinity column.  The column is prepared by hydrating about 5 grams of Affi-
gel 601 (boronate) in TE buffer (Maniatis) and packing the resin into a 20 x 2.5 cm glass 
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column.  This large column gives a good flow rate and allows the resin to expand and 
contract as pH varies.  This column is stored at 4˚C.   
At 4˚C, a 1 M TEABC (triethylammonium biocarbonate) buffer is prepared at pH 
9.3-9.6 by bubbling CO2 from dry ice through 141 mL triethylamine in 700 mL of water 
with mixing until the desired pH is reached.  Water is then added to 1 L.  The column is 
equilibrated with 250-300 mL of 1 M TEABC buffer.  The phosphorylation reaction mix 
(~25-50 mLs, typically), having been previously lyophilized, is dissolved in 10-25 mL of 
TEABC and added to the column.  The column is then washed with TEABC until A260 is 
<0.1.  The rNTPs are then eluted with bicarbonate buffer until A260 is again < 0.1.  This 
bicarbonate buffer is prepared by vigorously bubbling CO2 from dry ice through 
deionized water at 4º C with mixing for approximately one hour.  The pH of the 
bicarbonate buffer varies and is hard to measure accurately with a pH meter due to the 
dearth of counter ions in solution.  Complete elution may take 300-500 mL.  The early 
fractions contain a high concentration of TEA and are not pooled with the rest of the 
eluent. 
The clean eluent is pooled and lyophilized.  Ethanol precipitation may be used for 
further purification, but is usually unnecessary.  The labeled rNTPs are resuspended in 
deionized water to about 700 OD260 for T7 reactions.  The relative concentrations of the 
four rNTPs in this mix vary somewhat, but the mix can be used as is for RNA production 
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